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SUMMARY
In the majority of cases the diagnosis of acute 
pancreatitis in man requires confirmation from biochemical 
estimations and serum amylase is at present the commonest 
single biochemical test used to confirm this diagnosis. 
Hyperamylasaemia is regarded as the biochemical yardstick 
for acute pancreatitis despite very definite limitations 
which may not be recognised' by all clinicians. It has 
been clearly demonstrated that acute pancreatitis may be 
present without hyperamylasaemia, either due to a very 
severe inflammatory response which renders the pancreas 
unable to excrete amylase or, conversely, to a mild 
attack in which serum amylase is never elevated or returns 
to normal rapidly. It is also well recognised that 
hyperamylasaemia is not specific for acute pancreatitis, 
having been documented in several other acute abdominal 
conditions which may enter the differential diagnosis of 
acute pancreatitis. This significantly reduces the 
accuracy of serum amylase estimations in making the 
diagnosis of acute pancreatitis and also severely limits 
its sensitivity in detecting mild or sub-clinical attacks 
of pancreatic inflammation associated with small elevations 
in serum amylase.
In 1969 the amylase creatinine clearance ratio (ACCR) 
was proposed as a simple diagnostic test for acute
13.
pancreatitis. The ACCR is the renal clearance of amylase 
expressed as a percentage of the simultaneous creatinine 
clearance and can he calculated from 10 ml samples of 
venous blood and urine. The ACCR gives the information 
of an amylase clearance study without requiring a timed 
collection of urine and therefore can be used as a 
screening test for pancreatitis in the acute situation.
The initial evidence from the United States suggested 
that the ACCR may be an accurate and sensitive diagnostic 
test for acute pancreatitis and that a significant 
elevation of this ratio might be specific for this 
condition. This evidence was based on only three clinical 
studies with one further study questioning the specificity 
of an elevated ACCR for acute pancreatitis. At this time 
no work had been published from Britain or Europe, both 
areas of the world where the aetiology of acute 
pancreatitis often differs from that found in the United 
States. The aims of the studies in this thesis were to 
evaluate the role of the ACCR as a diagnostic test in 
British patients with acute pancreatitis and to attempt 
to demonstrate whether or not a significant elevation 
in the ACCR is related to pancreatic inflammation.
In two studies in this thesis a significant elevation 
in the ACCR was found to be 94% accurate in diagnosing 
acute pancreatitis confirmed by other methods and the
14,
ACCR was found to be the most successful single non- 
invasive diagnostic test for this condition. No patient 
without acute pancreatitis was found to have an ACCR 
above the upper limit of normal, including patients 
with acute abdominal conditions other than acute 
pancreatitis who had hyperamylasaemia. The ACCR was also 
found to have prognostic significance in acute 
pancreatitis being significantly related to the severity 
of each attack as defined by established prognostic 
factors and retrospective analysis of each patient's 
illness. An admission ACCR of over 10% in a patient 
with acute pancreatitis was found to be highly suggestive 
of a severe attack with a mortality greater than 50%,
The ACCR was found to remain abnormal for longer than 
serum amylase in acute pancreatitis and was judged to 
be of value in diagnosing acute pancreatitis in patients 
presenting to hospital with abdominal pain of over 48 
hours duration, _______
Post-cholecystectomy pancreatitis is well documented 
and significant ACCR elevations have been recorded after 
biliary surgery, A study was designed to confirm 
significant ACCR elevations after biliary surgery and 
demonstrate that this elevation was related to pancreatic 
inflammation. Intravenous Trasylol, a proteolytic 
enzyme inhibitor, was infused before, during and after
15,
biliary surgery in a group of patients and was found 
to significantly reduce the incidence of significant 
ACCR elevation on the first postoperative day. It 
has been shown in animal experiments that Trasylol can 
significantly modify the severity of acute pancreatitis 
when given prior to the induction of the pancreatitis 
and its failure to significantly influence the course 
of established acute pancreatitis in humans is almost 
certainly due to the fact that it is given once the 
inflammatory process is established. In this study it 
was possible to administer Trasylol prophylactically 
with results in keeping with the hypothesis that post- 
biliary surgery ACCR elevation is due to pancreatic 
inflammation.
Acute pancreatitis and elevated ACCR values have 
also been recorded after cardiac surgery performed using 
non-pulsatile cardiopulmonary bypass. The pancreatitis 
developing in this situation is thought to be ischaemic 
in origin and it has recently been shown that pulsatile 
cardiopulmonary bypass can improve tissue perfusion 
and the functioning of several organs during bypass,
ACCR changes during and after cardiac surgery performed 
using either non-pulsatile bypass or pulsatile bypass 
were studied. Significant ACCR elevation was observed 
in 9 out of 10 patients using non-pulsatile bypass but
16.
only 1 out of 10 patients using pulsatile bypass. The 
ACCR changes associated with cardiac surgery performed 
using cardiopulmonary bypass can therefore be 
significantly altered by the mode of perfusion employed. 
The evidence from this study suggests that the 
significant reduction in ACCR elevation during and after 
pulsatile bypass is related to normalisation of pancreatic 
function resulting from improved tissue perfusion.
In the light of the preceding evidence suggesting 
that an elevated ACCR in the absence of hyperamylasaemia 
may detect sub-clinical pancreatic inflammation, it was 
decided to screen the administration of Cimetidine for 
a possible relationship with acute pancreatitis as 
suggested in the literature. Acute and chronic 
administration of Cimetidine was tested and a small 
but significant elevation in the mean ACCR of patients 
was observed during the first 24 hours of intravenous 
Cimetidine therapy. All other factors detrimental to 
the pancreas appeared to be matched with the control 
group in this study and this finding may represent a 
genuine short term effect of Cimetidine on the pancreas.
The well documented increase in amylase clearance 
during the recovery phase of acute pancreatitis, when 
serum amylase levels are normal, has been shown to 
occur as a result of reduced amylase reabsorption in 
the renal tubules which is thought to be secondary to
17.
an as yet unidentified factor released by the pancreas. 
It has been demonstrated in this thesis that the ACCR, 
which measures amylase clearance, is significantly 
correlated with complement activation via the classical 
pathway in acute pancreatitis. Trypsin is known to 
activate complement via the classical pathway and it 
is therefore probable that Trypsin is responsible for 
the change in renal tubular reabsorption of amylase 
seen in acute pancreatitis.
The ACCR has therefore been shown to be a simple, 
accurate and sensitive test for pancreatic inflammation 
which has a definite role to play in the diagnosis of 
acute pancreatitis at the present time. The ACCR should 
complement serum amylase values in the diagnosis of 
acute pancreatitis and allow a more accurate interpret­
ation of hyperamylasaemia both above and below the 
diagnostic level for acute pancreatitis. This thesis 
has provided evidence that the ACCR can detect the 
presence of pancreatitis in the absence of hyper­
amylasaemia and this may lead to an increased use of 
the ACCR as a screening test for pancreatitis in 
situations where it may arise as a complication of 
treatment unrelated to the pancreas. Care must be 
taken, however, in the interpretation of ACCR values 
in the absence of hyperamylasaemia since there is no
18,
evidence that a significantly elevated ACCR is specific 
for acute pancreatic inflammation alone. The ACCR 
has been shown to be of prognostic value in an 
established attack of acute pancreatitis and its use 
alone, or in combination with other prognostic factors, 
may lead to patients with potentially severe acute 
pancreatitis receiving appropriate therapy at an 
earlier stage in their illness.
19.
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C H A P T E R  O N E
INTRODUCTION
1. THE DIAGNOSIS OF ACUTE PANCREATITIS
In 1929 the criteria for accepting a diagnosis of 
acute pancreatitis began to change from clinical judge­
ment to clinical suspicion confirmed by laboratory 
results. In that year Elman and his associates published 
a paper entitled "Value of blood amylase estimations in 
the diagnosis of pancreatic disease; a clinical study" 
and convincingly demonstrated an association between an 
abnormal elevation of serum amylase and acute 
pancreatitis (l). Not surprisingly this lead to a 
progressive increase in the frequency with which acute 
pancreatitis was diagnosed and to a lesser extent this 
increase in diagnostic frequency continues today (2,3),
In 1833 Payen and Persoz first precipitated a starch 
splitting product from malt which they named diastase 
(4), A similar substance was found in the blood in 
1846 by Magendie and named amylase after the Greek 
word 'amylon' meaning starch (5), Amylase was first 
measured quantitatively in animals by Foster in 1867 
(6) and in 1916 Stocks suggested that amylase activity 
in blood and urine might be a sensitive and reliable 
test for various pancreatic disorders (7).
21 .
Since 1929 numerous diagnostic tests for acute 
pancreatitis have been proposed and evaluated to a 
lesser or greater extent. Despite this, serum amylase 
remains the single test most commonly used to diagnose 
acute pancreatitis throughout the World, It is clear, 
however, that the measurement of serum amylase in acute 
pancreatitis has been so valuable that clinicians have 
frequently lost sight of its limitations (8), To date 
these limitations have not been fully overcome by any 
other test. The search for a simple test to take over 
from serum amylase in the diagnosis of acute pancreatitis 
has been hindered however by the stranglehold serum 
amylase estimation has over this diagnosis. Without a 
separate "gold standard" diagnosis which can be readily 
applied it is difficult to show that any one test is 
better than serum amylase alone when serum amylase is 
the normal yardstick used to diagnose acute pancreatitis. 
This thesis sets out to examine the role of the amylais^ 
creatinine clearance ratio (ACCR) as a simple diagnostic 
test for acute pancreatic dysfunction including clinically 
evident acute pancreatitis. Before setting out the 
evidence accumulated in these studies it is relevant 
to discuss the presently accepted biochemical tests 
considered diagnostic for acute pancreatitis in order 
to highlight their merits and weaknesses.
2. SERUM AMYLASE
Serum amylase Is usually elevated within 2-12 hours 
of the onset of acute pancreatitis and commonly returns 
to normal within 3 or 4 days. The response is more 
prompt and of greater magnitude if the gland is secreting 
at the time of injury (8), Pancreatic amylase reaches 
the blood stream via three routes; venous, lymphatic 
and peritoneal, the total absorption of amylase being 
greatest through the lymphatics (9,10,11), It has been 
shown to be impossible to predict the extent of pancreatic 
damage from the degree of abnormality of the serum amylase, 
(12),
Although serum amylase is usually elevated in acute 
or relapsing acute pancreatitis, it is also often 
elevated in conditions other than acute pancreatitis, 
a fact which limits the specificity of the test (13),
Table 1 lists 20 documented causes of hyperamylasaemia 
occurring without evidence of acute pancreatitis.
Because of these findings the minimum serum amylase 
level acceptable as diagnostic of acute pancreatitis 
is usually 4-5 times the upper limit of the normal range. 
This creates a 'grey area' between these two values 
in which a diagnosis of acute pancreatitis cannot be 
made or discarded with any certainty.
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TABLE 1
Causes of hyperamylasaemia without acute pancreatitis,
1, Biliary tract disease
2, Perforated peptic ulcer
3, Intestinal obstruction
4, Ruptured ectopic pregnancy
5, Mesenteric infarction
6, Afferent loop syndrome
7, Dissecting aortic aneurysm
8, Peritonitis
9, Acute appendicitis
10. Pancreatic carcinoma
11. Cerebral trauma
12. Bums
13. Post-operative hyperamylasaemia
14. Diabetic ketoacidosis
15. Renal transplantation
16. Pneumonia
17. Acquired bisalbuminaemia
18. Prostatic disease
19. Pregnancy
20. Drugs
Serum amylase values confirm the diagnosis' of 
acute pancreatitis in only 75-80% of cases (13).
In some patients with acute pancreatitis the serum 
amylase rapidly falls to normal, or within the grey 
area, before a blood specimen is taken; In others 
gland destruction is so complete that the serum amylase 
never rises, while in a third group of patients the 
presentation of acute pancreatitis may be so atypical 
that the serum amylase is not estimated. The lack 
of specificity of hyperamylasaemia for acute pancreatitis 
undoubtedly reduces the tests sensitivity in making 
this diagnosis. It must be remembered that hyper- 
amylasaemia does not provide a "yes" or "no" diagnosis 
of acute pancreatitis in 100% of cases but simply 
indicates the statistical probability of the presence 
of acute pancreatitis. At the upper end of the normal 
range of serum amylase values this probability is around 
5%, rising to 75% or 80% at the lowest level considered 
diagnostic for acute pancreatitis, r- The probability 
of the presence of acute pancreatitis rises from there 
but due to the lack of specificity of hyperamylasaemla 
never reaches 100%.
3. URINE AMYLASE
Hyperamylasurla per se Is not diagnostic of acute 
pancreatitis and may be seen In most of the disorders
25.
associated with hyperamylasaemla listed in Table 1*
In some of these conditions only urine amylase may 
be elevated with values in the range expected in acute 
pancreatitis (14). The level of amylase in the urine 
is significantly influenced by the excretory function 
of the kidneys and levels may vary considerably from 
hour to hour (13). These changes are accentuated 
in acute illnesses such as acute pancreatitis and 
result in a wide scatter of results in both normal 
and abnormal patients. Thus the sensitivity as well 
as the specificity of a single urine amylase estimation 
for the diagnosis of acute pancreatitis is poor and 
urine amylase results have been used mainly to 
calculate amylase clearance values. It has been noted 
however that the elevation of urine amylase in acute 
pancreatitis usually lags behind the serum level, since 
urinary levels may be still elevated for 7-10 days after 
serum levels have returned to normal (15,16,17).
4. AMYLASE ISOENZYMES
The amylase in serum and urine can be fractionated 
into two principle isoenzymes, the pancreatic type 
(p-type isoamylase) and the salivary type (s-type 
isoamylase) (18), There is now excellent evidence 
that the p-type isoamylase in serum and urine comes 
from the pancreas (18,19,20) and isoenzyme determination
zo ,
holds considerable promise for the future (19,21,22).
At present separation of isoenzymes requires polyacrylamide 
gel electrophoresis, chromatographic techniques or 
isoelectric focusing, all of which are sophisticated 
and complicated techniques not readily available in 
most hospitals. This therefore limits the clinical 
application of isoamylase estimations at the present 
time and renders them useless in the acute situation 
where a rapid result is required. The theoretical 
advantages of measuring the pancreatic isoenzyme of 
amylase are clear and the full investigation of the 
clinical relevance of these measurements only awaits 
the development of simplified routine analytical 
procedures.
5. AMYLASE CLEARANCE
Numerous investigators have demonstrated that the 
measurement of urine amylase excretion in acute 
pancreatitis is a more sensitive index of the disease 
than the serum amylase, rising relatively earlier and 
higher and persisting at abnormal levels for longer 
(15,16,17,23,24). Amylase clearance per se may be 
elevated above the normal range of 2.7 - 3.1 ml/min 
in hyperamy las aemia from any source although a level - 
greater than 4 ml/min is usually associated with acute
27.
pancreatitis (25). Amylase clearance measurements 
do have a place in helping to confirm the diagnosis 
of acute pancreatitis in patients whose serum amylase 
values just fail to reach the minimum diagnostic 
level for the disease (26). The main drawback to 
the routine use of amylase clearance is the fact that 
a timed urine collection is required to calculate the 
results. There is evidence that a short period of 
urine collection, i.e. 2-4 hours is just as accurate 
as a 12 or 24 hour collection in acute pancreatitis 
(27), but even this imposes definite restrictions on 
the use of the test in the acute situation. For this 
reason amylase clearance has not been used as a 
diagnostic screening test in many units treating acute 
pancreatitis. The amylase creatinine clearance ratio 
(ACGR) provides a means of calculating the renal 
clearance of amylase without the need for a timed 
collection of urine and will be discussed in the nextT™ 
chapter.
6. LIPASE
Serum lipase has long been recognised as a useful 
clinical measurement in acute pancreatitis and it has 
been appreciated for years that serum lipase tends 
to remain abnormal in acute pancreatitis longer than 
does serum amylase (28). Lipase determination in
28.
pancreatic disease has, however, not been used 
extensively because of methodological problems 
associated with the Cherry-Crandall assay which requires 
an incubation period of 24 hours, thereby rendering 
the test totally unsuited to the acute situation.
It has been recognised that, like amylase, abnormal 
serum lipase values occur in various peripancreatic 
diseases , and it is not yet clear whether the pancreas 
is the source of the elevated lipase in these cases (8). 
In 1974 a modification of a 5 minute turbidimetric 
determination of lipase was described and used to 
evaluate the diagnostic value of lipase in acute 
pancreatitis (29). Serum lipase was found to be 
elevated in 63% of the patients with acute pancreatitis, 
amylase was elevated in 70%, while one or other of 
the two enzymes was elevated in 83%. The diagnostic 
yield in acute pancreatitis may therefore be increased 
by measuring both seorum amylase and lipase. More 
evidence to support or refute this finding should be 
available in the near future following the sophistic­
ation of improved assay techniques for lipase.
7. PHOSPHOLIPASE, TRYPSIN AND DEOXYRIBONUCLEASE
These pancreatic enzymes are not commonly measured 
and changes occurring in acute pancreatitis have not 
been well documented. Serum phospholipase rises in
29.
acute pancreatitis along with serum lipase and amylase 
but the particular situations in which one enzyme 
might be preferred to another for diagnostic use 
awaits further evaluation (8). Serum trypsin activity 
also increases during an attack of acute pancreatitis 
but its specificity awaits evaluation in studies in 
various clinical states that enter into the differential 
diagnosis of acute pancreatitis. Its diagnostic 
sensitivity must also be compared with other established 
enzyme measurements in a large number of patients with 
acute pancreatitis. These steps in the evaluation of 
the usefulness of trypsin estimation in acute pancreat­
itis await a simplification of the analytical technique 
(8). Serum deoxyribonuclease at present also requires 
a complicated analysis for its estimation but interest 
in this enzyme has been stimulated by claims that it is 
only elevated in pancreatic disease (30), and that
elevated levels specifically reflect pancreatic necrosis 
(31). These claims require full investigation and at 
present deoxyribonuclease estimation is not regarded 
as a routine diagnostic test in acute pancreatitis.
The aim of the work presented in this thesis was 
to evaluate the amylase creatinine clearance ratio in 
a clinical context and assess its role as a diagnostic 
test for acute pancreatit dysfunction and clinically 
evident acute pancreatitis. The studies have been
30.
presented in chronological order and each project 
has been discussed separately using the knowledge 
available in the literature at the time of completing 
the study. In the final chapter (Chapter 8) the 
results and implications of each study are discussed 
in the light of present knowledge and the findings 
from all the studies integrated to produce an assess­
ment of the role of the amylase creatinine clearance 
ratio in acute pancreatic dysfunction.
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C H A P T E R  T W O  
THE AMYLASE CREATININE CLEARANCE RATIO
The indirect nature of the diagnosis of the majority 
of cases of human acute pancreatitis presents a problem. 
If the correct diagnosis is to be reached in every case 
then a test is required which is specific for acute 
pancreatic inflammation and 100% reliable at indicating 
the presence of that disease. The ideal test should 
also be simple and quick to perform, and the analytical 
procedures required should be readily available in any 
hospital laboratory. None of the diagnostic tests 
mentioned in the last chapter meet up to all these 
requirements and it seems unlikely that any diagnostic 
test for acute pancreatitis will do so in full in the 
near future. However, there is room for improvement 
in the diagnosis of acute pancreatitis in practice 
and a challenge exists to find a diagnostic test to 
fulfil more of the criteria stated above than those 
already available.
Dr. Michael Levitt and his colleagues, working in 
Minneapolis, first described the concept of the amylase 
creatinine clearance ratio (ACCR) in a paper published 
in 1969 (32), This study set out to examine the 
relationship between serum amylase, urine amylase 
and the renal clearance of amylase in patients with
33,
various conditions including acute pancreatitis and 
chronic renal failure. The renal clearance of 
creatinine was also estimated and this stimulated the 
authors to express amylase clearance as a percentage 
of the simultaneous creatinine clearance (ACCR).
It was observed that the ACCR could be calculated 
from spot samples of venous blood and urine, thus 
simplifying the clearance estimation by removing 
the need for a timed urine collection thus:
Canu __ 
Ccr"^
(Am) urine ^ Volume
X 100
(Am) serum X Time
(Cr)
(Cr)
urine
serum X
Volume
Time
(Am)
(Am)
urine
serum X
(Cr) serum 
(Cr) urine
where C = clearance 
Am = amylase 
Cr = creatinine
volume and time - urine collection
this leaves a formula which can be solved quickly and 
easily from a 10 ml sample of venous blood and a 10 ml 
sample of urine collected at around the same time as 
the blood.
In Levitt's study the ACCR was noted to be markedly 
and consistently elevated in 12 patients with alcohol 
induced acute pancreatitis, giving a mean value of 
6,6% and a minimum value of 4.5% within the first 
four days of the illness (32). Eighteen hospitalised 
patients with a variety of acute and chronic diseases 
thought not to involve the pancreas had a mean ACCR 
of 3.1% with two of this group having an ACCR of 
> 4.5%, Pancreatitis, however, could not be excluded 
in these two cases after more detailed examination of 
their records. Fifty-two healthy medical students 
had a mean ACCR of 2.3% +0.1 s.e.m., the highest 
value being less than 4.5%. The ACGR of 13 patients 
with stable chronic renal insufficiency (mean creatinine 
clearance “ 28 ml/min) was found to be similar to that 
of the control patients despite a highly significant 
reduction in amylase clearance per se. This finding 
lead the authors to suggest that the ACCR might be 
an index of amylase clearance which could be used to 
compare the renal handling of amylase in patients with 
various degrees of renal impairment. They noted that 
this feature of the ACCR might also be of value in 
the diagnosis of acute pancreatitis in some patients. 
The ACCR was also found to remain elevated for 3-4 
days in acute pancreatitis before falling towards 
normal. The serum amylase levels, on the other hand.
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tended to fall precipitously towards normal in 24-48 
hours.
Little was heard of the ACCR after Dr, Levitt's 
publication until 1974 when Dr. Dreiling and his group 
from New York (33) and Dr. Warshaw and his group from 
Boston (34) published independent ACCR studies on a 
total of 215 patients with acute pancreatitis, mainly 
due to alcohol abuse. Both groups concluded that in 
acute pancreatitis the ACCR was superior to the 
diagnostic significance of serum or urine amylase 
determinations alone, with a diagnostic accuracy for 
acute pancreatitis of around 88%. Warshaw's group 
suggested in 1975 that the ACCR could accurately 
determine between pancreatic and non-pancreatic 
hyperamylasaemia, taking the upper limit of normal 
for the ACCR as being 5.3% as opposed to Dr. Dreiling's 
value of 4% (35,36). Warshaw reported that the ACCR 
remained below 5.3% in 44 patients with hyperamylasaemiaT 
due to disease other than pancreatitis, but was over 
5.3% in all but 3 of 42 patients with acute pancreatitis, 
This suggested that the renal handling of amylase was 
specifically altered in acute pancreatitis and provided 
a basis for using the ACCR in the differential diagnosis 
of hyperamylasaemla.
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In 1976 Orda et al published the first ACGR study 
in animals (37). Using a guinea pig model, and inducing 
acute pancreatitis by injecting sodium taurocholate into 
the pancreatic parenchyma, they found a significant 
elevation in the ACCR in guinea pigs with acute 
pancreatitis compared to controls, animals with acute 
duodenal perforations and animals with small bowel 
infarction. The ACCR was found to be superior to 
serum amylase alone in identifying animals with acute 
pancreatitis and was also noted to rise significantly 
in animals with acute pancreatitis but without hyper­
amylasaemia. In short this animal study confirmed 
the main findings of the human ACCR studies and the 
authors concluded without reservation that the ACCR 
should be a valuable diagnostic test in acute 
pancreatitis in man. Between 1975 and 1976 Dr. Levitt 
and his colleagues. Dr. Warshaw and his colleagues 
and Drs, Long and Grider from Philadelphia all 
published evidence to explain why the renal clearance 
of amylase is increased during an attack of acute 
pancreatitis (38,39,40,41,42). There were three 
possible explanations for this observation, i.e.
1) an increased serum concentration of a very
rapidly cleared isoamylase in acute pancreatitis;
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2) an increased glomerular permeability to amylase 
in acute pancreatitis;
3) a decreased renal tubular reabsorption of filtered 
amylase in acute pancreatitis.
All three groups of workers came to the firm conclusion 
that no new isoenzymes of amylase were formed during 
an attack of acute pancreatitis and that the permeability 
of the glomerulus to amylase was unaltered. That left 
reabsorption of amylase in the renal tubules as the 
most likely site for the defect and this was supported 
by Johnston et al who showed that the excretion of 
B2-microglobulin, a low molecular weight protein 
similar to amylase and known to be reabsorbed in the 
renal tubules, was greatly increased in acute 
pancreatitis (39). There was presumed to be a 'tubular 
dysfunction factor' which comes into play in acute 
pancreatitis and inhibits the tubular handling of 
amylase and other low molecular weight proteins.
No evidence was available concerning the nature of 
this 'factor' or whether it functioned in conditions 
other than acute pancreatitis.
In 1975 Levine et al reported significant elevation 
of the ACCR during 10 episodes of diabetic ketoacidosis 
and in 6 patients with bums (43). No patient studied 
had an elevated serum amylase level and although there
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was no proof that these patients did not have acute 
pancreatitis, these observations cast doubt on the 
specificity of an elevated ACCR for acute pancreatitis. 
A further note of caution appeared in the literature 
in September 1976 from Cape Town when Berger et al 
reported a significant elevation in the ACCR in 2 out 
of 5 patients with an acute duodenal perforation as 
well as 6 out of 8 patients with acute pancreatitis 
(44). No good evidence was put forward in this small 
study however to show that the patients with acute 
duodenal perforations did not also have pancreatitis. 
The normal ACCR value in this study, which was not 
actually quoted, was obtained from 10 control patients, 
an insufficient number from which to determine an 
accurate normal range. The results of this paper 
must therefore be regarded as suspect although they 
cannot be overlooked.
In the studies reported in this thesis the ACGR 
was always calculated according to the formula 
described by Levitt (32). Amylase activity in serum 
and urine was measured using the Phadebas amylase 
test kit (Pharmacia diagnostics, Uppsala, Sweden) 
which for all studies except that reported in Chapter 
3 had bovine serum albumin added to increase the 
sensitivity for amylase, especially in the urine.
The addition of bovine serum albumin to the test
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has been shown to slightly increase the value of the 
ACCR from the same samples of blood and urine (45).
The substrate in the test kit is a water insoluble 
cross-linked starch polymer carrying a blue dye.
This polymer is hydrolysed by oC -amylase to form 
water soluble blue fragments,' The absorbance of 
the blue solution on a photometer measuring 620 + 5 nm 
is a function of the OC -amylase activity of the 
sample. Serum and urine creatinine levels were all 
measured using a Technicon All autoanalyser which 
operates using a modified Jaffe reaction (46) based 
on the fact that creatinine forms a red complex in 
alkaline picrate solution. Amylase activity has 
been expressed in international units per litre, 
while serum and urine creatinine levels have been 
expressed as micromoles per litre and millimoles 
per litre respectively.
The original paper describing the ACCR suggested—  
calculating the ratio from simultaneous samples of 
venous blood and urine (32). In practice this can 
be difficult unless the patient has a bladder catheter 
in place and this problem becomes most obvious in 
the first few hours after admission to hospital when 
the diagnostic accuracy of the ACCR for acute 
pancreatitis should be most useful. The ACCR was 
therefore estimated in 6 patients with no known
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pancreatic disease who had indwelling bladder catheters 
in place. The 10 ml urine samples were taken from the 
catheter tubing at the time of venous blood sampling 
and again one hour later. Two ACCR values were 
calculated for each patient using the results from the 
two urine samples. The mean ACCR values for each 
urine sample time were not significantly different 
(1,42% + 0.2 s.e.m. stat and 1.49% + 0.25 s.e.m. after 
one hour) and statistical evaluation of the individual 
pairs of results for each patient showed no significant 
difference (Paired Student's t test). To test the 
reproducibility of the ACCR over a 12 hour period 
in a patient without acute pancreatitis venous blood, 
samples were taken from one 21 year old male admitted 
electively with a sternal deformity at 9 a.m., 1 p.m.,
5 p.m. and 9 p.m. the same day. A urine sample was 
obtained within an hour of each blood sample and the 
ACCR results were as follows; 0.9%, 1%, 1.1%, 0.95% 
respectively. These results indicate that the ACCR  ^ . 
is a reproducable test within a short period of time 
in a normal person and that the urine sample required 
for ACCR estimation can be taken during the hour 
following venous blood sampling without significantly 
altering the ACCR results.
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1, INTRODUCTION
The literature on the ACCR up to 1976 was in general 
encouraging. No clinical publications, however, had 
appeared from Great Britain or Europe and it was felt 
that the first step in determining the usefulness of 
this ratio in the diagnosis of acute pancreatitis in 
this country should be to confirm the basic findings 
from the U.S.A., i.e. the sensitivity and specificity 
of the ACCR as a diagnostic test in acute pancreatitis.
An important difference in studies of acute pancreatitis 
in Great Britain and North America lies in the aetiology 
of the disease. The majority of cases of acute 
pancreatitis reported from large centres, in North America 
are related to alcohol abuse whereas in Glasgow and the 
remainder of the United Kingdom gallstones are the 
commonest related factor (51%) with alcohol abuse only 
accounting for up to one quarter of the patients (26,
47). The aetiology of acute pancreatitis had not 
been taken into account in previous studies involving 
the ACCR. It was therefore decided to attempt to 
verify the changes in the ACCR previously noted in
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the UoSoA. during an attack of acute pancreatitis 
since this seemed to be the logical first step in 
evaluating the use of the ACCR as a diagnostic test 
in patients with acute pancreatitis in the United 
Kingdom.
2. PATIENTS AND METHODS
i) Patients Studied
One hundred and twenty two patients admitted 
to the Western Infirmary, Glasgow were studied. 
Venous blood and urine samples for analysis and 
calculation of the ACCR were obtained within 24 
hours of admission to hospital in all cases. 
Particular attention was paid to this point with 
patients admitted suffering from acute surgical 
conditions. The 122 patients were divided into 
four groups for analysis of the ACCR data based 
on the diagnosis reached in each patient's case
by the surgical team responsible for his or her 
management without prior knowledge of the ACCR 
results. Two groups of patients had chronic 
conditions that were either related or unrelated 
to the gastrointestinal tract. The remaining 
two groups had acute abdominal conditions including 
acute pancreatitis. The diagnostic details of the
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four groups of patients studied were as follows -
Group 1 - 40 elective patients acting as controls
with chronic conditions unrelated to 
the gastrointestinal tract.
Breast lumps - 8
Inguinal hernia - 8
Varicose veins - 5
Stitch sinus - 4
Soft tissue injury - 4
Scrotal swelling - 4
Neck lump - 2
Undescended testis - 1
Ingrowing toenail - 1
Adrenal adenoma - 1
Phimosis - 1
Ovarian cyst - 1
Group 2 - 30 patients admitted electively to the
Western Infirmary, Glasgow, with chronic 
gastrointestinal conditions but with no 
evidence of past or present involvement 
of the pancreas.
Chronic duodenal ulceration - 9
Upper gastrointestinal neoplasms - 5
(excluding the pancreas)
Cholelithiasis - 5
Simple anorectal conditions - 5
Lower gastrointestinal neoplasms - 4
Chronic gastric ulcer - 1
Diverticular disease - 1
Group 3 - 35 patients admitted to the Acute Surgical
Receiving Unit of the Western Infirmary,
Glasgow, with acute abdominal conditions 
diagnosed independently as being -
Acute cholecystitis - 9
Acute peptic ulceration - 7
Perforated viscus - 7
Alcohol induced 'gastritis* - 4
Ureteric colic - 3
Acute appendicitis - 2
Acute diverticulitis - 1
Mesenteric adenitis - 1
Pelvic inflammatory disease - 1 ' ______
The diagnosis of cholelithiasis, peptic ulcer­
ation, diverticular disease and ureteric colic 
was confirmed at a later date by appropriate. 
radiology. The diagnosis of perforated viscus, 
acute appendicitis and mesenteric adenitis 
was made at laparotomy which post-dated the 
collection of samples for calculation of the
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ACCR. Two cases of acute gastritis 
were confirmed at upper gastrointestinal 
endoscopy while a gynaecologist 
supported the diagnosis of acute 
pelvic inflammatory disease.
Group 4 - This group comprised 17 patients
admitted to the Acute Surgical Receiving 
Unit of the Western Infirmary, Glasgow 
and diagnosed as having acute pancreatitis 
without prior knowledge of ACCR values.
ii) The Diagnosis of Acute Pancreatitis
The diagnostic criteria for acute pancreatitis 
used in the Western Infirmary, Glasgow, were 
a cotnpatable history and clinical findings plus 
a serum amylase of ) 1200 iu/1. The diagnosis 
could of course also be made at laparotomy.
Fourteen of the 17 patients had a serum amylase 
> 1200 iu/1 within the first hour of their 
hospital admission. In 4 of these 14 patients 
however the serum amylase subsequently fell to 
^ 1200 iu/1 when a blood sample was taken for 
ACCR estimation within the first 24 hours in 
hospital.
4 / .
The diagnosis of acute pancreatitis was made 
at laparotomy in 3 patients, all of whom had serum 
amylase values within the normal range for the 
Western Infirmary on admission (upper limit of 
normal; 300 iu/1). A laparotomy was carried 
out in all 3 cases within 24 hours of admission 
to hospital and post-dated the collection of blood 
and urine for ACCR estimation. A laparotomy 
diagnosis was made in each case by an experienced 
surgeon of consultant or senior registrar grade.
No histology, however, is available to confirm the 
macroscopic findings at operation. ACCR estimations 
were carried out daily where possible in patients 
with acute pancreatitis.
iii) Calculation of the ACCR
The ACCR was calculated using the formula of 
Levitt et al described earlier (32). This ratio
of clearances allows urine volume and collection 
times to be cancelled out of the clearance equation 
leaving only simultaneous concentrations of amylase 
and creatinine in blood and urine to be estimated. 
In practice a urine sample (10 ml) obtained within 
one hour of a venous blood sample (10 ml) was 
regarded as satisfactory for ACCR estimation. 
Amylase was estimated using a Phadebas reagent kit.
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while creatinine was measured on a Technicon All 
autoanalyser as described in Chapter 2.
3. RESULTS
i) Patient Details
Table 2 shows the number, mean age and sex 
distribution of the patients in each of the four 
groups studied. No statistically significant 
difference was found between the four groups with 
regard to these factors.* Table 3 shows the aetiology 
of the acute pancreatitis in the 17 cases studied. 
Viral titres were not carried out in the patient 
labelled as having idiopathic acute pancreatitis 
and therefore this not unknown form of the condition 
(5 out of 116 cases in Glasgow) may have explained 
the aetiology in this case (48).
ii) Creatinine Results
Table 4 shows the mean serum and urine 
creatinine values used to calculate the ACCR in 
the four groups of patients studied. There was 
no statistically significant difference between 
the four groups in either mean serum or urine 
creatinine values. Two patients in group 2,
4 patients in group 3, and 1 patient in group 4 
had a serum creatinine value above the upper limit 
of normal (115 pmol/l) at the time of ACCR
TABLE 2
Age axid s ex distribution of the groups of patients 
studied,'
G r o u p s 
2 3
Number of Patients 40 30 35 17
Mean Age (Yr) 44 54 48 54
Male (M) 22 17 20 12
Female (F) 18 13 15 5
M/F Ratio 1.2 1.3 1.3 2
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TABLE 3
The aetiology of acute pancreatitis in the 17 cases 
studied.
Cholelithiasis - 9 (53%)
Alcohol Abuse - 6 (35%)
Hyperparathyroidism - 1
Idiopathic - 1
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TABLE 4
Serum and urine creatinine values used to calculate 
the ACCR in the four groups of patients (mean + s,e,m. )
Serum ----- Creatinine    ■ ■ Urine
(pmol/1)
Group
1 86,7 ± 2.5 11,400 + 80
2 86,4 + 4,5 12,600 + 1,300
3 86.2 + 4,4 12,900 + 1,400
4 90,1 + 5,3 10,900 ± 1,700
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calculation. None of these patients had established 
renal failure or subsequently developed renal failure 
during their admission and it was felt at the time 
that the elevated serum creatinine values could be 
explained by dehydration,
iii) Amylase Results
The mean serum amylase values used to calculate 
the ACCR in the four groups of patients are shown 
in Table 5 and plotted individually in Figure 1.
The mean serum amylase of patients with acute 
pancreatitis (1751 iu/l) was significnatly higher 
in the mean serum amylase values in the other 
three groups (p <, 0,001). It is interesting to 
note that the mean serum amylase for group 4 
patients within an hour of admission to hospital 
was 2893 iu/l which was considerably greater 
(p < 0,02) than the mean of the serum amylase 
values for group 4 used to calculate the ACCR 
during the first 24 hours in hospital. This 
illustrates the precipitous fall in serum amylase 
levels which is not infrequently observed in acute 
pancreatitis, A repeat blood sample was usually 
necessary in these patients in order to correspond 
with the urine sample and therefore two serum 
amylase values were often available within the
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TABLE 5
Serum and urine amylase values used to calculate the 
ACCR in the four groups of patients (mean + s.e.m,). 
Unpaired Student's t test.
Serum  Amylase ----- Urine
(I.U./L)
Group
1 190 i 10 338 ± 32
2 209 + 15 444 + 63
3 230 ± 19 + . 590 ± 68
4 1,751 ± 374 * 10,669 ± 3,308
* 4 > 1,2,3 for serum and urine amylase p 4 0,001 
4- 3 1 serum amylase p <^0,05
urine amylase p ^ 0,02
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Group 1 Group 2 Group 3 Group 4
Figure 1 Serum amylase values for the 4 groups of 
patients studied. Mean + 2 s^e.mo 
Unpaired Student'^s t test.
* 4 > 1, 2 & 3 
r* 3 > 1
p < 0.001
p < 0.05
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first 24 hours of hospital admission. Figure 1 
shows that at the time of sampling for ACCR 
calculation (within the first 24 hours in hospital) 
only 10 patients in group 4 had serum amylase 
values >• 1200 iu/l.' Three out of the remaining 
7 patients were diagnosed at laparotomy without 
hyperamylasaemia leaving 4 patients in whom the 
serum amylase had fallen to 1200 iu/l within a 
few hours of admission.
Patients with acute abdominal conditions 
of non-pancreatic origin (Group 3) were found to 
have a significantly higher mean serum amylase 
than the control patients in group 1 (p ^ 0.05:
Table 5). Seven per cent of the patients in group 
1 (3) and group 2 (2) had a serum amylase value 
above the upper limits of normal for the Western 
Infirmary Biochemistry Laboratory (300 iu/l).
In group 3, however, 20% of the patients (7) 
had a serum amylase value in excess of 300 iu/l.
The changes in urine amylase concentration 
essentially mirrored the findings with serum amylase 
(Table 5: Figure 2). The mean urine amylase value 
for group 4 was found to be significantly greater 
than the mean values for groups 1, 2 and 3 
(p 0.001), despite a large scatter round the 
mean in group 4. The mean urine amylase concentration
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Figure 2,
Group 3 Group 4
Urine amylase values for the 4 groups 
of patients studied. Mean + 2 s.e.m. 
Unpaired Student*s t test.
4 > 1, 2
** 3 >. 1
p < 0.001 
p 0.025
for group 3 was found to be significantly greater 
than the mean concentration for control patients 
(Group 1) - p < 0.02.
The ratio of serum amylase to urine amylase 
was calculated for each patient using the data employed 
to calculate the ACCR. The mean values of this ratio 
for each group of patients is shown in Table 6. No 
statistically significant difference was noted between 
the mean serum to urine amylase ratios of the four 
groups of patients. Patients with acute pancreatitis 
(Group 4) tended to have a lower ratio indicating a 
relative increase in excretion of amylase. This was, 
however, of little diagnostic use due to the wide 
range of values seen in patients with no evidence of 
acute pancreatitis.
iv) ACCR Results
The ACCR values for the four groups of patients 
within 24 hours of admission are plotted in Figure 
The mean ACCR in patients with acute pancreatitis 
(6%) was significantly higher than the mean ACCR 
values found in groups 1, 2 and 3 (p C 0.001),
There was no significant difference between the 
mean ACCR values of patients without acute 
pancreatitis (Groups 1, 2 and 3), each being 1.5%.
The 7 patients (20%) with acute abdominal conditions 
other than acute pancreatitis (Group 3) who had a
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TABLE 6
Ratio of serum to urine amylase for the four groups 
of patients (mean + S.Do)
Group SA/UA
1 0.74 + 0.5
2 0.72 + 0.4
3 0.95 + 1.4
4 0.21 + 0.12
59.
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9-
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SS
Group 1 (^ oup2 Group 3 Group 4
Figure 3. ACCR values.for the 4 groups of patients 
studied. Mean + 2 s.e.m.
Unpaired S t u d e n t f  test.
* 4 > 1 ,  2 & 3  - p <  0,001
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serum amylase value > 300 iu/l had a mean ACCR 
of 1,34%. This was not significantly different 
from the mean ACCR value for the control patients 
in group 1 (1,5%).
The mean ACCR value for the 105 patients 
in groups 1, 2 and 3 with no evidence of acute 
pancreatitis was found to be 1,498% with a standard 
deviation of 0,64, The 95% upper confidence limit 
of this mean based on the standard deviation was 
taken to be 2,8%, The upper limit of normal for 
the ACCR in the Western Infirmary, Glasgow was 
therefore judged to be 3%. Figure 3 shows that 
no patient in groups 1, 2 or 3 had an ACCR value 
over 3%, whereas 16 out of 17 (94%) of the
patients diagnosed Independently as having acute
pancreatitis had an ACCR value 3%. One 63 
year old male patient had an ACCR of 2,8% but 
was diagnosed at laparotomy as having mild 
pancreatitis secondary to cholelithiasis. His 
serum amylase on admission to hospital was mthin
the normal range at 130 iu/l.
The diagnostic accuracy in acute pancreatitis 
of various biochemical parameters used individually 
or to calculate the ACCR are shown in Table 7,
The ACCR shows an encouraging diagnostic accuracy 
of 94% in this small study and betters serum
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TABLE 7
Diagnostic accuracy of various biochemical estimations 
in patients with acute pancreatitis.
ACCR = 94%
Serum amylase = 83%
Urine amylase = 76%
Serum amylase “ 59%
SA/UA = 35%
( > 3% within 24 hours)
( > 1200 i.u./l on admission)
( > 1700 i.u./l)
( > 1200 i.u./l within 24 hours 
of admission)
( 4, 0.125 within 24 hours of 
admission)
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amylase alone which shows a maximum accuracy of 
83% within one hour of admission.
Figure 4 shows daily serum amylase and ACCR 
results obtained from a 89 year old woman admitted 
with acute pancreatitis and entered into the dtudy 
as a group 4 patient. It can be seen that her 
serum amylase value rapidly fell (within 48 hours) 
to below the diagnostic level (1200 iu/l). The 
ACCR however remained elevated for significantly 
longer and did not fall below 3% until the eighth 
day. This pattern was observed in the majority 
of the 17 cases of acute pancreatitis studied, 
the ACCR usually returning to normal between the 
fifth and tenth days,
4, DISCUSSION
i) Diagnostic Accuracy
The results of the study were encouraging
in as much as they confirmed most of the findings 
of the American workers in this field to date.
The findings in this study also indicate that ACCR 
changes in acute pancreatitis are independent of 
the aetiology of the disease (i.e. alcohol 
gallstones in U.S.A, and gallstones ^  alcohol in 
GoB,)o In this study the mean admission ACCR of 
patients with pancreatitis secondary to gallstones
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(6.4% + 2.7 S.D.) was not significantly different 
from the value found in patients with alcohol 
abuse as the cause for their attack of acute 
pancreatitis (5.6% j- 1.7 S.Do).
The study confirmed that the ACCR is a simple 
test to perform and that its great advantage over 
amylase clearance per se lies in the ability to 
calculate the ratio using a single sample of urine 
only. The ability to calculate an expression of 
amylase clearance in this way allows a clearance 
value such as the ACCR to be used as a screening 
test in an acute situation if so desired. All 
four estimations required to calculate the ACCR 
can be performed rapidly in most biochemical 
laboratories and the ACCR could be available 
within an hour of taking the blood and urine 
samples.'
A serum amylase value and the ACCR could be 
used together as a biochemical screen for acute 
pancreatitis. The results of this study support 
the conclusions of Dreiling et al (33) that 
simultaneous evaluation of the serum amylase and 
the ACCR is superior to the diagnostic significance 
of amylase determinations alone. In this study 
an ACCR performed during the first 24 hours in
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hospital was 94% accurate in diagnosing acute 
pancreatitis. Over the same period of time 
serum amylase alone was only 59% accurate in 
making this diagnosis. Time was found to be 
an important factor when considering serum amylase 
estimations. The diagnostic accuracy of serum 
amylase alone rose to 83% when the blood sample 
was taken during the first hour of admission as 
opposed to some time during the first 24 hours 
of admission. No other single biochemical 
parameter estimated in this study was found to 
be superior to the ACCR in terras of diagnostic 
accuracy for acute pancreatitis.
ii) Normal Range of the ACCR
The upper limit of normal for the ACCR in 
the Western Infirmary, Glasgow was calculated to 
be 3%, based on results from 105 pafcients with no
evidence of acute pancreatitis. Levitt et al found 
the upper limit of normal for the ACCR in 52 healthy 
volunteers to be 4% (32). A similar figure was 
obtained by Dreiling et al for 125 normal controls 
(33). Warshaw obtained an upper limit of normal 
for the ACCR of 5.3% from 46 normal subjects in 
Boston (35). The figure of 3% calculated from 
study is lower than previously recorded in humans
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but similar to the value obtained in a guinea 
pig study by Orda et al - normal <  3.2% (37).
Because of possible variations in analytical 
technique it has been suggested that a normal 
range of ACCR values should be established in 
each centre using the ratio (32). This is 
obviously important in early work with this 
ratio since if upper limits of normal for the 
ACCR of 4 and 5.3% were adopted in this study 
the diagnostic accuracy of the test in acute 
pancreatitis would be reduced to 77% and 53% 
respectively,
iii) Sensitivity of the ACCR
In this study an ACCR of over 3% (mean 5.2%) 
was obtained within the first 24 hours of admission 
from 3 patients without significant hyperamylasaemia 
(mean serum amylase = 233 iu/l) who were all found 
to have acute pancreatitis at laparotomy. In these 
3 patients the history of abdominal pain was of 
greater than 48 hours duration and it is therefore 
probable that initially abnormal serum amylase 
levels had fallen to within the normal range prior 
to admission. This hypothesis is supported by the 
results of serial estimations of serum amylase 
and the ACCR carried out in this study on patients
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with acute pancreatitis. The ACCR in these cases 
always returned to the normal range after serum 
amylase had done so and therefore this demonstrated 
that an elevated ACCR without hyperamylasaemia 
could indicate resolving acute pancreatic 
inflammation. This observation also indicates 
that the ACCR may be a more sensitive diagnostic 
test for acute pancreatic inflammation than is 
serum amylase alone. It is therefore possible 
that the ACCR will be of particular diagnostic 
value for acute pancreatitis in cases presenting 
to hospital with abdominal pain of over 48 hours 
duration. These patients may have serum amylase 
values within the normal range or within the 'grey 
area' between the upper limit of normal (300 iu/l) 
and 1200 iu/l and it is in these cases particularly 
that the ACCR could be of extreme value.
iv) Specificity of the ACCR
In this study an ACCR value of ^  3% was 
specific for acute pancreatitis. The mean ACCR 
values of the other three groups of patients were 
identical, an encouraging finding in the presence 
of statistically significant hyperamylasaemia in 
the group of patients with acute abdominal conditions 
excluding acute pancreatitis (Group 3), There
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cannot be conclusive proof that no patient in this 
group had acute pancreatitis, but the highest 
serum amylase recorded was 520 iu/l in a patient 
with a perforated anterior duodenal ulcer, one of 
several conditions represented in this group 
which have been associated with non-pancreatic 
hyperamylasaemia (14,35,49,50,51,52,53,54).
v) Urine Amylase
The changes in urine amylase observed in 
this study broadly mirrored the changes in serum 
amylase. Mean urine amylase values were significantly 
elevated in patients with acute pancreatitis (Group 
4) and also, but to a lesser extent, in patients 
with non-pancreatic acute abdominal conditions 
(Group 3). Great variability, however, was noted 
in the urine amylase results and the diagnostic 
discrimination of this test for acute pancreatitis 
was found to be poor. These findings are in 
agreement with the conclusions relating to urine 
amylase estimations in a recent review article 
(13). The ratio of serum to urine amylase was 
found to be decreased in acute pancreatitis but 
these changes were found not to be statistically 
significant due to the wide scatter of results in 
patients without acute pancreatitis. Like urine
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amylase alone this ratio was found to be of poor 
diagnostic specificity for acute pancreatitis.
vi) Conclusions
In conclusion therefore the main findings of 
this study were interpreted as follows:
1. The ACCR is simple to estimate and could 
be used as a screening test in a patient 
presenting with acute abdominal pain.
2. The ACCR is a reliable and sensitive 
index of acute pancreatic inflammation in 
humans,
3. The diagnostic accuracy of the ACCR in 
acute pancreatitis does not appear to be 
significantly influenced by the aetiology 
of the disease*
4. In this study a significant ACCR elevation
was only observed in patients with acute 
pancreatitis and not in patients f^ith 
other acute and chronic gastrointestinal 
conditions.
5. The sensitivity of the ACCR for acute
pancreatic inflammation may give a diagnostic 
advantage over serum amylase alone In patients 
who present to hospital more than 48 hours 
after the onset of abdominal pain.
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C H A P T E R  F O U R
THE AMYLASE CREATININE CLEARANCE RATIO 
FOLLOWING CHOLECYSTECTOMY
1. INTRODUCTION
i) Diagnostic Problems in Acute Pancreatitis
The study outlined in Chapter 3 confirmed the 
earlier finding that the ACCR was very likely to be 
significantly elevated in the presence of acute 
pancreatic inflammation. In only 3 out of the 17 
cases of pancreatitis studied, however, was a 
direct diagnosis of acute pancreatitis made at 
laparotomy. In the remaining 14 cases the diagnosis 
of acute pancreatitis was made indirectly on the 
basis of appropriate clinical findings and hyper­
amylasaemia, the two factors that lead to the 
diagnosis of acute pancreatitis in the majority 
of cases throughout the World. It is well ______
established, however, that acute pancreatitis is 
not the only intra-abdominal source for hyper­
amylasaemia (14). Despite this knowledge the 
clinical impression of acute pancreatitis is 
seldom documented by pathological examination of 
tissue or by some other unequivocal 'gold standard' 
technique. How then can one prove a new test is 
better than amylase measurements when amylase
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values remain the usual yardstick used to 
diagnose acute pancreatitis?
This question poses a difficult practical 
problem in the evaluation of the ACCR in humans.
In the ideal situation ACCR values should be 
estimated before, during and after anticipated 
attacks of acute pancreatitis with all other 
factors equal. This is obviously not possible 
in the human, to whom this test is most applicable, 
and therefore some other method of approach has 
to be sought in an attempt to demonstrate a 
relationship between the ACCR and acute pancreatic 
inflammation.
ii) Post-Operative Pancreatitis
Operative trauma to the upper abdomen is a 
well established cause of acute pancreatitis, 
especially when the operation involves the biliary 
tract (55,56,57,58). Interference with the 
Sphincter of Oddi is said to be the most important 
single factor in promoting this form of acute 
pancreatitis (59). Post-operative acute 
pancreatitis is notoriously difficult to diagnose 
clinically and carries a high mortality (47).
In 1977 Donaldson et al published a study of 
25 patients undergoing elective cholècystectomy
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in whom the ACCR was estimated before and after 
surgery in an attempt to further define the 
incidence of acute pancreatic dysfunction 
following cholecystectomy (60). Twenty eight 
percent of all patients were found to have a 
significantly elevated ACCR ( y 5.5%) 24 hours 
after cholecystectomy while 70% of patients who 
underwent exploration of the common bile duct 
had a significantly elevated ACCR. None of the 
patients, however, developed clinical acute 
pancreatitis and only one had an abnormal serum 
amylase level. Did these findings represent 
* sub-clinical* pancreatic inflammation detected 
by a rising ACCR or was the correlation spurious?
It seemed that an attempt could be made 
to answer this question by making use of the fact 
that the incidence of pancreatic inflammation
following cholecystectomy could be manipulated---
in at least two ways, i.e.
1. through the presence or absence of 
common bile duct exploration, or -
2. by using the drug Trasylol (Aprotinin) 
as a prophylaxis against acute 
pancreatitis.
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Trasylol is a proteolytic enzyme inhibitor which 
has been advocated as being beneficial in the 
treatment of established acute pancreatitis.
An initially encouraging study (61) was followed 
by good evidence of the drug’s ineffectiveness 
in established acute pancreatitis (62,63), It 
should not be forgotten, however, that animal 
studies have shown clearly that Trasylol is very 
effective at modifying the inflammatory response 
of the pancreas when given prior to the insult 
inducing the inflammation (64,65,66), In the 
majority of cases of human acute pancreatitis 
prophylaxis is not possible. In post-cholecystectomy 
acute pancreatitis, however, prophylaxis is 
eminently possible and this situation presents 
a genuine indication for the use of Trasylol in 
the operative and peri-operative period, especially 
in patients with a high risk of developing acute 
pancreatitis i.e. patients with known common bile 
duct stones or a past history of acute pancreatitis.
It was therefore decided to study ACCR changes 
in a group of patients undergoing cholecystectomy, 
half of whom had been randomised to receive Trasylol 
during and after surgery. It was hoped that this 
study would confirm Donaldson’s finding of
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significant ACCR elevation following cholecystectomy 
and also extend this finding by showing that 
Trasylol prophylaxis significantly modifies the 
ACCR changes. A result of this sort would add 
weight to the evidence that=^an elevated ACCR was 
in fact related to pancreatic inflammation.
ill) Thermolability of Amylase
In 1974 Warshaw demonstrated that over 90% 
of the amylase activity in saliva and pancreatic 
juice was destroyed by heating at 65^C for 15 
minutes (67). In normal serum only 44% of total 
amylase was thermolabile under these conditions 
but this rose significantly to 84% in acute 
pancreatitis (68). These observations suggested 
that the estimation of thermolabile amylase in 
blood and urine may be a simple way to monitor 
changes in the pancreatic isoenzyme of amylase 
which would otherwise require sophisticated 
techniques for identification (14). Thermolabile 
amylase estimation was therefore requested on 
all samples of venous blood and urine obtained 
during this study in an attempt to demonstrate 
that any significant ACCR changes observed were 
related to pancreatic dysfunction.
76.
2. PATIENTS AND METHODS
i) Patient Details
Eighty patients admitted to wards G6 and 7 
of the Western Infirmary, Glasgow, were studied.
All patients were admitted for elective surgery 
with either cholelithiasis or minor non-abdominal 
conditions requiring surgery under general 
anaesthesia. These patients were divided into 
three groups for analysis of amylase and ACCR 
data.
Group 1
This group was made up of 29 patients 
admitted for elective non-abdominal surgery under 
general anaesthesia. These patients acted as a 
control group for the study and were suffering 
from the following conditions:
Inguinal hernia 10
Varicose veins 7
Breast lump 5
Pilonidal sinus 3
Ganglion 2
Stitch sinus 2
Group 2 (NoT.)
This group contained 22 patients who underwent 
cholecystectomy with or without operative 
cholangiography and common bile duct exploration.
Cholelithiasis was confirmed at surgery in each 
case and all operations were performed by surgeons 
working in one surgical unit at the Western 
Infirmary (Professor Sir Andrew Watt Kay’s Unit).
Group 3 (T)
In this group were 29 patients similar in 
all respects but one to patients in Group 2.
These 29 patients were randomly selected to receive 
Trasylol before, during and for 24 hours after 
their cholecystectomy. The use of this drug was 
approved by the Ethical Committee of the Western 
Infirmary, Glasgow, and each patient in this 
group gave informed consent to its use. Trasylol 
was administered intravenously in a dosage of 
1,200,000 units/24 hours added to either 5% 
dextrose, normal saline or Ringer’s lactate 
infusions. Administration was started at least 
one hour prior to induction of anaesthesia and 
was continued for 24 hours after surgery.
No significant difference was noted in 
either age or sex distribution between the control 
patients (Group 1) and the patients in Groups 2 
and 3 with gallstones (Table 8).
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TABLE 8
Age and sex distribution of the patients studied 
Mean + s.e.m.
S E X A G E
(f7
Î (ft %
Controls 10 (35%) 19 (65%) 52 + 6 48 + 3
Group 2 6 (26%) 16 (74%) 50 + 3 56 ± 3
Group 3 7 (33%) 22 (66%) 5 3 + 3 50 + 2
Groups 2 & 3 13 (25%) 38 (75%) 51 + 4 5 2 + 2
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No significant difference in these parameters was 
noted between the two groups of gallstone patients. 
Table 9 details the grade of surgeon who performed 
the cholecystectomies in Groups 2 and 3, while 
Table 10 details the incidence of intra-operative 
radiology, common bile duct exploration and 
previous pancreatitis,
ii) Experimental Protocol
A 10 ml sample of venous blood and a 10 ml 
sample of urine were collected within one hour of 
each other from each patient in the study on the 
day before surgery and again on the morning of 
the first post-operative day. Samples were stored 
and analysed in one run for total amylase and 
creatinine as already described in Chapter 2,
The ACCR was calculated using the formula described 
by Levitt (32). Amylase thermolability was assessed 
by repeating a Phadebas amylase estimation after 
heating the serum or urine sample at 65^ for 15 
minutes. The thermolabile amylase content of the 
sample was calculated by subtracting the result of 
the second estimation from the first and then 
expressing this figure as a percentage of the 
total amylase content, i.e.
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TABLE 9
Grade of surgeon who performed cholecystectomy.
Group 2 Group 3
Consultant 8 9
Senior Registrar 4 7
Registrar 8 10
Senior House Officer 2 3
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TABLE 10
Incidence of operative cholangiography, duct 
exploration, and previous pancreatitis.
Group 2 Group 3
Simple cholecystectomy 17 22
+Operative cholanglogram 3 2
+Common bile duct explor- « _
ation
Previous pancreatitis 2 3
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Thermolabile amylase % = Msul.t A - Result- B
Result A 1
where Result A = preheated value 
Result B = postheated value
3, RESULTS
i) Pre-Operative Data
The pre-operative values for serum amylase, 
thermolabile serum amylase, urine amylase, thermo­
labile urine amylase, serum creatinine, urine 
creatinine and the ACCR for study Groups 1, 2 and 
3 are shown in Table 11. No statistically significant 
difference was noted between the groups in these 
pre-operative values and therefore the data from 
the 80 patients was combined to provide a pre­
operative control value for each estimation derived 
from 80 observations (Table 12).
A mean pre-operative, and therefore presumably 
normal, ACCR value of 2% + 0.24 s.e.m. was obtained 
from the 80 patients in this study. In order to 
increase the population sampled and thus the 
accuracy of this mean and its distribution, the 
ACCR results from 105 patients with no evidence of 
acute pancreatitis detailed in the previous study. 
This gave 185 patients with no evidence of acute 
pancreatitis and produced a mean ACCR of 1.75%
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TABLE 12
Preoperative mean values derived from all 80 patients 
studied - mean + s.e.m.
1. Serum amylase iu/1 = 203 + 12
2. Thermolabile serum amylase % = 29.4 + 2.4
3. Urine amylase iu/l = 307 + 48
4. Thermolabile urine amylase % - 60,9 + 4
5. Serum creatinine yimo 1/1 = 98 + 3.6
6. Urine creatinine ^ pmol/1 = 8221 + 879
7. ACCR = 2.0 + 0.24
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with a standard deviation of 1.53 and a standard 
error of the mean of 0.12. The upper limit of 
normal of this mean ACCR and the distribution 
around it was calculated to be 5%,
None of the variables measured in the study 
was significantly altered by general anaesthesia 
and surgery carried out on control patients in 
Group 1 (Table 13). This finding suggests that 
the ACCR is not influenced by general anaesthesia 
per se, nor by minor tissue injury at a site 
distant from the pancreas.
ii) Amylase Results
The changes in serum and urine amylase values 
recorded after cholecystectomy in Groups 2 and 3 
are shown in Table 14 and Figures 5 and 6. No 
significant change was noted in mean serum amylase 
and only two patients in each cholecystectomy group
had a serum amylase value above the upper limit of 
normal (300 iu/l) on the first post-operative day. 
One cholecystectomy patient not receiving Trasylol 
(Group 2) had a serum amylase of 1668 iu/l on the 
first post-operative day. This patient had 
undergone a cholecystectomy plus removal of one 
stone from the common bile duct and it must be 
assumed that post-operative pancreatitis occurred
8b.
TABLE 13
Pre and post-operative results for the control 
patients (Group 1: n = 29) mean + s.e.m.
Pre-op Post--op
1. Serum amylase iu/l 190 ± 8 194 ± 6
2. Thermolabile serum amylase % 32 ± 1.6 32.8 ± 2
3. Urine amylase iu/l 285 ± 20 259 ± 38
4. Thermolabile urine amylase % 61.5 ± 6 63.8 ± 5.5
5. Serum creatinine jumo 1/1 96 ± 4 99 ± 8
6. Urine creatinine jumol/1 8685 ± 658 9976 ± 1210
7. ACCR % 1.84 + 0.2 1.61 ± 0.25
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TABLE 14
Serum and urine amylase values before and after 
cholecystectomy (mean + s.e.m.).
Unpaired Student’s t test.'
Pre-op Post-op 
Group 2 Group 3
Serum amylase 
iu/l
Urine amylase 
iu/l
203 + 12 
307 + 48
174 + 28 
752 + 96*
156 + 18 
613 + 84'*'
Post-op y pre-op * p < 0.001 
p < 0.01
I.U./L
300-
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200-
100-
T_
1
Pre-op Controls
29
N X
22
T.
29 I
Post-op
Figure 5, Mean serum amylase of pre-operative
and post-operative study groups + s.e.m.
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i.u . / l
750-
**
500-
250-
Pre-op C
29
NT
22
Post-op
T
29
Figure 6 Mean urine amylase of pre-operative and 
post-operative study groups + s.e.m. 
Unpaired Student's t test.
T > pre-op 
NT > pre-op
p < 0.01
p < 0.001
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in this case. This patient's ACCR on the first 
post-operative day was 8.6%, in keeping with 
a diagnosis of acute pancreatitis.
A significant elevation in urine amylase 
concentration, indicating increased amylase clearance 
by the kidneys, was noted from the post-operative 
samples obtained from patients in both chole­
cystectomy groups.' This effect was most marked, 
however, in patients who had not received Trasylol 
(Group 2). Figure 6 illustrates this change in 
urine amylase which was striking in the absence 
of significant hyperamylasaemia (Figure 5).
iii) Thermolabile Amylase Results
The changes in thermolabile serum and urine 
amylase values recorded after cholecystectomy in 
patients in Groups 2 and 3 are shown in Table 15 
and Figures 7 - 9 .  A statistically significant 
increase in thermolabile serum amylase was observed 
after cholecystectomy in patients not receiving 
Trasylol (p O.Ol). In these patients (Group 2) 
mean thermolabile serum amylase increased from 29% 
to 53% following surgery, similar to the figure 
of 55% obtained by Donaldson from 14 patients 
with resolving acute pancreatitis (68). In
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TABLE 15
Serum and urine thermolabile amylase values before 
and after cholecystectomy (mean + s.e.m.). 
Unpaired Student's t test.
Post-op
Pre-op Group 2 Group 3
Thermolabile serum 
amylase % 29.4 + 2.4
53 + 6.4* 40 + 9.6
Thermolabile urine 
amylase % 50.9 + 4 63 + 5 62 + 4
* Post-op > pre-op: p <.0.01
92.
L total
amylase
ControlsPre-op
Post -  op
Figure 7. Mean thermolabile serum amylase in
pre-operative and posl-operative study 
groups + s.e.m. Unpaired Student's t test.
* NT pre-op - p < 0.01
93,
% Total 
amylase
50-
25-
Pre-op C
29
NT
22
T
29
Post-op
Figure 8, Mean thermolabile urine amylase in
pre-operative and post-operative study 
groups + s.e.m.
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i.u./l
750 -
500
250 -
Thermolabile serum omylose
Thermolabile urine amylase
serum
amylase
urine
amylase
Pre - op
serum
omylose
urine
omylose
Post-op
Figure 9, Serum and urine amylase composition 
before and after cholecystectomy.
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patients receiving Trasylol (Group 3) the mean 
thermolabile serum amylase rose to 40% following 
surgery, but this increase was not found to be 
statistically significant. These changes are 
illustrated in Figure 7.
The percentage of thermolabile urine amylase 
remained remarkedly constant and was uninfluenced 
by cholecystectomy (Figure 8). The absolute amount 
of thermolabile urine amylase excreted, however, 
increased following cholecystectomy in keeping 
with the increase in total urine amylase observed. 
Changes in total and thermolabile serum and urine 
amylase in patients undergoing cholecystectomy 
without Trasylol, (Group 2) are shown in Figure 
9.
iv) ACCR Results
No significant changes were noted in either 
serum or urine creatinine values following 
cholecystectomy with or without the use of Trasylol. 
A significant rise in the mean post-operative ACCR 
value was seen in Groups 2 and 3 after chole­
cystectomy (Table 16; Figure 10). This rise was 
more marked in those patients who had not received 
Trasylol (Group 2) and the mean ACCR value in this 
group (9.5%) was significantly greater than the
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TABLE 16
ACCR changes following cholecystectomy with and without 
Trasylol cover - mean + s.e.m. Unpaired Student’s t test.
Pre-op
Post-op 
Group 2 Group 3
ACCR % 2.0 + 0.24 9.5 + 2.4* 5.6 + 1.6*
Post-op y pre-op: * p ^ 0.001
p <  0.01
Group 2 > Group 3: p ^ 0.05
%
«-I
M e a n t  S.e.
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* *10-
5-
ControlPre-op N.T.
22
T.
29
Post-op
Figure 10. Mean ACCR values for pre-operative and 
post-operative study groups + s.e.m. 
Unpaired Student's t test.
* T > pre-op - p < 0.01
** NT > pre-op - p < 0.001
NT > T - P <, 0.05
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mean value (5.6%) of patients In Group 3 who had 
received Trasylol (p 0.05).
A post-operative ACCR of greater than 5% 
was recorded in a total of 24 patients (47%) who 
underwent cholecystectomy. Sixteen out of 22 
patients (73%) not receiving Trasylol (Group 2) 
had a post-operative ACCE. greater than 5% whereas 
only 8 patients out of 29 (28%) who received 
Trasylol showed this rise in the ACCR. The 
difference in ACCR elevation between the two groups 
is statistically highly significant (p <, 0.005). 
Cholecystectomy alone lead to a post-operative 
ACCR of greater than 5% in 51% of patients in 
Group 2 but only 18% of patients in the Trasylol 
group (Group 3). This difference is statistically 
significant (p ^ 0.025). Cholecystectomy plus 
common bile duct exploration lead to a post­
operative ACCR of greater than 5% in 100% of 
patients in Group 2 but only 57% of patients in 
the Trasylol group. This difference just fails 
to reach statistical significance. An ACCR of 
over 5% was not recorded in any of the 80 pre­
operative samples and did not occur in the control 
group (Group 1) post-operatively.
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4. DISCUSSION
1) Pre-Operative Data
This study has confirmed that the ACCR may 
be significantly elevated in the first 24 hours 
after cholecystectomy; demonstrated that these 
ACCR changes may be significantly reduced by the 
use of the proteolytic enzyme inhibitor Trasylol, 
and provided evidence via thermolabile amylase 
measurements that the ACCR changes observed were 
related to pancreatic dysfunction.
The pre and post-operative studies on the 
29 control patients in Group 1 demonstrated that 
general anaesthesia plus minor surgery at an extra 
abdominal site had no significant influence on 
either serum or urine amylase in total or thermo- 
labile form or on the ACCR itself (Figures 5 - 8 ,
10). The pre-operative results obtained from
Groups 2 and 3 showed no statistically significant 
difference for each value estimated and when means 
were calculated for all gallstone patients these 
were similar to the means obtained in the control 
patients (Table 11). A mean for each test in the 
study was therefore calculated from the 80 pre­
operative samples (Table 12). There was no reason 
to suspect the presence of pancreatic dysfunction
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in any of the patients prior to surgery. Two 
patients in Group 2 and 3 patients in Group 3 
had suffered a previous attack of acute 
pancreatitis but on admission for elective 
surgery all were asymptomatic with normal serum 
amylase values (Table lO).
The mean pre-operative serum thermolabile 
amylase value was found to be 29.4%. This is 
lower than Donaldson's value of 44% (58) but 
in keeping with Warshaw's finding of between 10 
and 30% r(57). The corresponding percentage for 
urine in this study was found to be 50.9%. 
Donaldson's mean value was 87% and although 
higher, our two studies agree on a significant 
increase in the percentage of thermolabile 
amylase in the urine compared to serum. The 
difference in our figures probably reflects the 
smaller numbers in Donaldson's study (serum = 
23; urine =11). It is well recognised that 
the pancreatic isoenzyme of amylase is prefer­
entially excreted by the kidneys (3 8 ) .  Iso­
electric focusing techniques have demonstrated 
that pancreatic amylase represents about one 
third of the amylase in normal serum but about 
70-80% of the total urine amylase. Pancreatic
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amylase is thus excreted three to four times 
more rapidly than is the remainder of the serum 
amylase. Thermolabile amylase also demonstrates 
this point and it is tempting to suggest that 
the thermolabile component of amylase as defined 
in this study is related to the pancreatic iso­
enzyme of amylase. Donaldson has produced further 
evidence to support this concept by showing that 
patients with pancreatic pseudocysts maintain a 
high percentage thermolabile amylase in their 
serum until the cysts resolve or are drained 
(69).
ii) Amylase Data
Cholecystectomy and its related procedures 
did not significantly alter the mean serum 
amylase concentration of the patients studied 
within the period of observation. One patient
who did not receive Trasylol, however, developed 
biochemical evidence of acute pancreatitis on the 
first post-operative day. An overall incidence 
of 4% for acute pancreatitis following biliary 
tract surgery has been quoted in the literature 
(55), Based on this figure two attacks of acute 
pancreatitis could have been expected during
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this study and the one attack documented using 
the standard diagnostic criteria was therefore 
consistent with the phenomenon under study.
Although total serum amylase concentration 
was not altered significantly, cholecystectomy 
lead to a significant increase in thermolabile 
serum amylase in patients not receiving Trasylol 
(Group 2). This change was marked and closely 
resembled the change in thermolabile serum 
amylase seen in resolving acute pancreatitis 
(68). If one postulates that this represents 
an increase in pancreatic amylase in the serum 
secondary to pancreatic inflammation, then this 
helps explain the findings with urine amylase 
in this study. Cholecystectomy lead to a 
significant increase in total urine amylase 24 
hours after surgery which was most marked in 
patients who had not received Trasylol. Any 
increase in pancreatic amylase in the serum 
would be preferentially cleared by the kidneys 
resulting in some increase in the urine amylase 
concentration. Since urine normally contains 
70-80% pancreatic amylase this relatively small 
change in serum amylase composition would be 
unlikely to be reflected in urine amylase
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composition which did in fact remain stable in 
this study. The significant increase in amylase 
in the urine observed in this study cannot simply 
be explained by an increase in pancreatic amylase 
production and excretion. Overall renal excretion 
of amylase must have been increased to explain 
the amount of urine amylase excreted in the 
absence of hyperamylasaemia. This situation 
clearly occurs during the resolution of an attack 
of acute pancreatitis when there is good evidence 
that the renal excretion of amylase is increased 
due to a reduction in amylase reabsorption in 
the proximal renal tubules (39). This would be 
a logical explanation for the amylase findings 
in this study and would link these observations 
with pancreatic inflammation. Figure 9 outlines 
the changes in serum and urine amylase values 
in patients undergoing cholecystectomy without 
Trasylol cover and highlights the following points:
1, No change in total serum amylase 
concentration after cholecystectomy,
2, Significant increase in thermolabile 
serum amylase percentage after chole­
cystectomy.
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3, Significant increase in total urine 
amylase concentration after chole­
cystectomy,
4, No change in thermolabile urine amylase 
percentage after cholecystectomy.
5, Significant increase in thermolabile 
urine amylase concentration after 
cholecystectomy,
iii) ACCR Data
The mean ACCR value for the 80 patients in 
the study was combined with the value from the 
105 patients without acute pancreatitis in the 
study presented in Chapter 3 to give a mean ACCR 
of 1,75%, The mean was not used in this study 
for comparative purposes but was used to calculate 
an upper limit of normal for the test based on 
185 observations. This was found to be 5% and 
this figure was used in this study when assessing 
a significant ACCR rise for an individual.
The mean ACCR of patients undergoing chole­
cystectomy was found to be significantly elevated 
on the first post-operative day. This finding 
was entirely in keeping with the amylase excretion 
data discussed above. There is therefore little 
doubt that amylase excretion was increased in the
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first 24 hours following cholecystectomy. The 
question remains, however, as to whether or not 
this increased amylase excretion was related 
in any way to pancreatic inflammation,
iv) Effect of Trasylol
In this study the use of the proteolytic 
enzyme inhibitor Trasylol was found to:
1, Significantly diminish the rise in 
percentage thermolabile serum amylase 
after cholecystectomy.
2, Diminish the rise in urine amylase 
concentration after cholecystectomy.
3, Significantly diminish the mean ACCR 
after cholecystectomy,
4, Significantly reduce the number of 
patients with an ACCR greater than 5% 
after cholecystectomy,
5, Reduce the number of patients with an 
ACCR greater than 5% after cholecystectomy 
plus biliary radiology and common duct 
exploration.
The significant effects resulting from the use of 
Trasylol suggest that pancreatic inflammation was 
responsible for the observed changes in amylase
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excretion and the ACCR. Trasylol, when present 
in an adequate concentration in the blood prior 
to induction of acute pancreatitis, can modify 
the acute pancreatic inflammatory process by 
the partial inhibition of trypsin and other related 
proteolytic enzymes. This protective role has 
been well documented in animal models (64,65,66). 
The opportunity to give Trasylol before the 
induction of pancreatitis seldom arises in the 
human. Two exceptions to this rule are prior 
to cholecystectomy and before ERCP in high risk 
cases.
The postulated mechanisms to explain the 
changes observed in this study are shown in 
Figure 11. Trasylol is believed to act both 
directly on the pancreas and indirectly on the 
enzyme 'broth* released by the inflamed gland.
One of the systemic effects of acute pancreatitis 
appears to be to reduce the reabsorption of 
amylase from the renal tubules. This in turn 
leads to an increase in amylase excretion as 
measured by the ACCR and an increase in urine 
amylase concentration. These changes in acute 
pancreatitis should be reduced, although obviously 
not abolished, by the action of Trasylol. The
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FIGURE 11
Suggested mechanism of action of Trasylol in 
reducing the ACCR after cholecystectomy*
1
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Vasoactive substances
Renal tubular function
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stronger the stimulus to acute pancreatitis, 
the less should be the protective effect of 
Trasylol. The findings in the study have supported 
this hypothesis by showing a reduced protective 
effect of Trasylol on the ACCR in patients under­
going common bile duct exploration as well as 
cholecystectomy.
It may be of course that acute pancreatic 
inflammation had no part to play in the changes 
in amylase excretion observed in this study. It 
is possible that general anaethesia plus 
cholecystectomy per se resulted in the changes 
seen. It would however be difficult to explain 
the observed effects of Trasylol in the absence 
of any pancreatic involvement. The pancreatic 
dysfunction which may have been detected by the 
ACCR changes in the study is of course essentially 
sub-clinical. There can be no absolute proof 
from the study that this postulated pancreatic 
inflammation actually existed, and the evidence 
in favour of ACCR changes being related to 
pancreatitis accumulated from this study remains 
indirect. This will probably remain the case in 
human studies at least until a gold standard 
diagnosis of pancreatic inflammation other than 
histology is described.
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The evidence in favour of ACCR elevation 
being related to pancreatic inf 1 animation is 
however increasing, albeit mainly indirect.
From the first two studies it can be stated 
that :
1. The ACCR is significantly elevated in 
acute pancreatitis.
2, No significant elevation in the ACCR 
has been found in acute abdominal 
conditions other than acute pancreatitis,
3. The ACCR is a more sensitive diagnostic 
test for pancreatic inflammation than 
serum amylase,
4, Significant ACCR elevation occurs 
following cholecystectomy,
5, Post-cholecystectomy ACCR elevation can 
be significantly reduced by Trasylol 
given before, during and after surgery.
6. Exploration of the common bile duct 
added to cholecystectomy produces the 
greatest post-cholecystectomy ACCR 
changes.
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The ACCR may therefore be a sensitive index 
of pancreatic inflammation which could be applied 
as a monitor and might be of use after biliary 
surgery to detect patients developing pancreatic 
inflammation. The ACCR might also be used in 
other situations where pancreatic inflammation 
has been shown to occur occasionally in order to 
assess the incidence of sub-clinical pancreatitis,
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C H A P T E R  F I V E
THE AMYLASE CREATININE CLEARANCE RATIO 
FOLLOWING CARDIOPULMONARY BYPASS
1. INTRODUCTION
Evidence has been cited in the last chapter to 
show that acute pancreatitis is a well documented 
complication of biliary tract surgery and is thought 
to be related to operative trauma to the pancreas or 
sphincter of Oddi (55, 56,57,58,59). Post-operative 
acute pancreatitis has more recently been documented 
following cardiac surgery performed using conventional 
non-pulsatile cardiopulmonary bypass (CPB) (57,70,71,72). 
Feiner has reported a 16% incidence of unexplained 
pancreatitis at autopsy in patients dying after cardiac 
surgery (73) and this figure is far higher than the 0.1% 
incidence of acute pancreatitis expected after procedures 
not involving the area of the pancreas (58).
Operative trauma to the upper abdomen cannot readily 
be implicated in the aetiology of pancreatitis in cardiac 
cases. Evidence from Feiner (73), Warshaw (74) and 
Foulis (75) suggests that pancreatic tissue ischaemia 
may be an important aetiological factor in post-bypass 
pancreatitis. The ACCR has been found to be significantly 
elevated without clinical signs of acute pancreatitis 
after non-pulsatile CPB (76,77). Patients undergoing 
thoracotomy without CPB did not exhibit a significant
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rise in the ACCR.’ The studies so far outlined in 
this thesis have provided indirect evidence that the 
ACCR may be a sensitive index of acute pancreatic 
dysfunction, A significant ACCR elevation observed 
following cardiac surgery may therefore be indicative 
of pancreatic ischaemia during non-pulsati1e CPB.
There is now convincing evidence of organ system 
dysfunction during non-pulsatile CPB, including a 
progressive rise in peripheral vascular resistance 
associated with renin-angiotensin activation and 
tissue hypoperfusion (78,79,80,81), During the last 
five years reliable systems have been developed to 
deliver pulsatile CPB. Improved metabolic and 
haemodynamic responses have been documented during 
and after pulsatile CPB, e.g. improved tissue oxygen 
consumption (82,83), reduced activation of the renin- 
angiotensin system (84,85), and reduced indices of
kidney and brain damage consistent with improvement-----
in overall tissue perfusion (83,86,87,88,89).
If pancreatic tissue ischaemia during non-pulsatile 
CPB is an important aetiological factor in post-bypass 
pancreatitis, then pulsatile CPB might be expected 
to reduce the incidence of this complication. It was 
decided to use the ACCR to test this hypothesis in 
view of the fact that significant ACCR elevation had 
already been demonstrated following non-pulsatile
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CPB (76,77). Moreover the apparent sensitivity of 
the ACCR for subclinical pancreatic dysfunction makes 
it a suitable screening test in a situation such as 
this where the expected incidence of clinical acute 
pancreatitis is low. The ACCR was therefore measured 
before, during and after cardiac surgery performed 
using both non-pulsatile and pulsatile CPB in an 
attempt to further elucidate the nature of post­
bypass acute pancreatitis.
2. PATIENTS AND METHODS
i) Patients
Twenty adult patients admitted to Glasgow 
Royal Infirmary for elective open heart surgery 
were arbitrarily allocated to pulsatile or non- 
pulsatile study groups. No patient had a past 
history of pancreatic disease and all had normal 
renal function prior to surgery. In the pulsatile 
group, 5 patients underwent valve replacement and 
5 had coronary artery bypass grafting. In the 
non-pulsatile group 7 patients underwent valve 
replacements while 3 had coronary artery bypass 
grafting.
ii) Bypass Details
The pre-operative and operative details for 
both groups are shown in Table 17. There was no
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significant difference between the groups in 
the factors documented. In all cases general 
anaethesia was induced with sodium thiopentone 
and maintained with nitrous oxide, oxygen and 
intravenous morphine. The bypass circuit was 
primed with 2 litres of Ringer’s lactate solution 
and a Cobe-StBckert cardiopulmonary bypass pump 
was used in both groups. This pump is a modified 
roller pump based on a large ’stepping’ motor with 
low pump-head inertia which allows rapid 
acceleration and deceleration of the pump-head.
The pump motor is driven via a control module 
which allows the operator to set the frequency, 
amplitude and duration of pulsation delivered by 
the pump-head. The pump can also run as a standard 
roller pump, delivering non-pulsatile blood flow.
A digital record for instantaneous mean or phasic 
pump flow is displayed on the pump module while 
the radial artery pressure profile is relayed to 
a pen recorder to record the production of a true 
pulsatile arterial waveform. This pump was used 
in both groups according to the following protocol; 
Non-Pulsatile Group
The pump in non-pulsatile mode throughout 
the period of perfusion. In the non-pulsatile 
group the classical ripple pattern was seen in
I X / ,
the radial artery waveform and at no time was 
pressure fluctuation greater than 10 mmHg.
Pulsatile Group
The pump in non-pulsatile mode until left 
ventricular ejection ceased. Thereafter pump in 
pulsatile mode at 72 pulses/minute until left 
ventricular ejection restarted. Pump reverted 
to non-pulsatile mode until end of perfusion.
Pump settings for pulsatile flow were as previously 
described (84). Pulse run time was 55% of the 
total cycle length, delay time was 0 and the 
automatic control was set to 80% to ensure a 
small constant forward flow through the system.
In each patient pulse pressure in the radial 
artery was greater than 25 mmHg with a rise time 
in the pressure wave less than 20% of the total 
cycle length.
Normothermic bypass was used in both groups, 
myocardial protection being achieved using topical 
hypothermia and aortic root flush cardioplegia.
iii) ACCR Calculation
Spot samples (10 ml) of venous blood and 
urine were obtained simultaneously at the following 
times :
1. before surgery
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2.* during surgery but before bypass -
3. during bypass (approximately midpoint)
4. during surgery but after bypass
5. daily, for the first five post­
operative days.
Amylase was estimated using a Phadebas reagent 
kit while creatinine was measured on a Technic on All 
auto-analyser. The ACCR was calculated using the 
standard formula described by Levitt (32). The 
mean ACCR of 185 patients admitted to the Western 
Infirraary, Glasgow, with no evidence of pancreatic 
disease has previously been shown to be 1.75%.
The upper limit of normal for the ACCR for the 
purposes of this study was accepted as 5%, a 
figure based on the 95% confidence limit of the 
mean just described. The criterion for a significant 
elevation in the ACCR in this study was taken to 
be two consecutive ACCR values greater than 5% 
in any patient,
3. RESULTS
i) Amylase Data
No patient in this study developed clinical 
signs of post-operative acute pancreatitis. Two 
patients in the pulsatile group had a serum amylase 
value greater than the upper limit of normal (300 iu/1)
but neither value approached the diagnostic 
level for acute pancreatitis (1200 iu/1). Five 
patients in the non-pulsatile group (50%) had a 
serum amylase value of greater than 300 iu/1 and 
in one of these patients a serum amylase level of 
1224 iu/1 was recorded during bypass. No 
significant difference however was found between 
the mean serum amylase values of the pulsatile and 
the non-pulsatile groups at each sample time 
(Figure 12), On the first post-operative day the 
mean urine amylase concentration of patients in 
the non-pulsatile group (969 iu/l) was found to 
be significantly higher ( p >  0.01) than the 
corresponding value for the pulsatile group patients 
(252 iu/1) - Figure 13,
ii) ACCR Data
The ACCR was found to be significantly 
elevated, as defined above, in 9 patients in the—  
non-pulsatile group (90%) and 1 patient in the 
pulsatile group (10%). This difference was found 
statistically (Fisher’s exact test) to be highly 
significant (p ^ 0.001), Figure 14 shows the 
mean ACCR values for the 10 patients in the non- 
pulsatile group. The mean ACCR for these patients 
was found to be significantly greater than the
1 2 0 ,
SERUM 
AMYLASE 
(:.u./ I)
300 n
100-
PRË-OP -^ “THEATRE 2 4 53
POST-OP days
Figure 12« Mean serum amylase values for pulsatile 
group (open circles) and non™pulsatile 
group (closed circles)^
1 2 1 .
URINE
AMYLASE
{i.u./î)
1000
500-
PRE-OP ^TH EA TR E “9^ 2 3 4 5
POST-OP DAYS
Figure 13, Mean urine amylase values for pulsatile 
group (open circles) and non-pulsatile 
group (closed circles)„
Unpaired Student®s U test.
* Non-pulsatile y pulsatile - p 4, 0^01
1 2 2 .
5-
3-
1-
542 3PRE-O P  ^T H E A T R E -5 ^
POST-OP DAYS
Figure 14« Mean ACCR + Soe.m. for non-pulsatile 
group* Paired S t u d e n t t  test*
r* value > pre «“Op
** value > pre-op
p < 0.05 
p < 0,005
123.
pre-operative value during bypass, just after 
bypass and on the first two post-operative days.
The 10 patients in the pulsatile group did not 
show a significant rise in ACCR during CPB and 
their mean post-bypass ACCR values were not 
significantly greater than the pre-operative 
value (Figure 15). The mean ACCR results for 
the non-pulsatile group and the pulsatile group 
are combined in Figure 16, The patients in the 
non-pulsatile group had significantly higher 
mean ACCR values during bypass, just after bypass 
and on the first post-operative day. Pre-operative 
and pre-bypass mean ACCR values were similar for 
both groups.
iii) Clinical Progress
The post-operative clinical course was 
uneventful in all patients studied# In particular 
post-bypass haemodynamic status was stable, no 
forms of circulatory assistance was required, and 
all patients were extubated and breathing 
spontaneously within 24 hours of surgery. Significant 
post-operative renal insufficiency was not encountered 
in any patient studied. The mean post-operative 
maximum value for serum creatinine was 102 /mol/l 
in the non-pulsatile group and 109 yuraol/1 in the 
pulsatile group#
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4. DISCUSSION
i) Amylase Excretion
This study has confirmed previous reports 
that the renal clearance of amylase may be 
significantly increased during and immediately 
following non-pulsatile CPB (76,77). This is 
reflected in this study firstly by a significant 
increase in urine amylase concentration on the 
first post-operative day and secondly by a 
significant increase in the ACCR during non- 
pulsatile CPB and on the first two post-operative 
days. Increased amylase excretion in the presence 
of stable serum amylase levels, such as is seen 
in the resolution phase of acute pancreatitis, 
is thought to result from a reduction in amylase 
reabsorption from the renal tubules rather than 
a change in amylase isoenzyme structure or an 
increased filtration of amylase at the glomerular 
level (39,40,90). The precise mechanism leading 
to the reduction in the reabsorption of amylase 
in the renal tubules secondary to pancreatic 
inflammation is as yet unknown.
This general theory, however, is supported 
by the findings of Hennings and Jacobsen (77) 
who noted increased renal excretion of p2 micro-
iZ/.
globulin, a low molecular weight protein known 
to be reabsorbed in the renal tubules, following 
non-pulsatile CPB. There is some evidence that 
competitive inhibition of amylase reabsorption 
secondary to non-specific low molecular weight 
proteinuria may also occur in the renal tubules 
(90). This may explain the raised ACCR values 
reported in conditions apparently unrelated to 
acute pancreatitis (43,90,91), although, due to 
the problems in making a certain diagnosis of 
acute pancreatitis discussed earlier it is 
impossible to be sure that acute pancreatitis was 
not coexistant in the majority of these cases.
While the changes in renal clearance of amylase 
observed in this study are entirely in keeping 
with those expected in mild acute pancreatitis, 
the possibility of non-specific low molecular 
weight proteinuria causing these changes cannot—  
be excluded,
ii) Effect of Pulsatile CPB
The study has shown that the abnormal amylase 
excretion observed following non-pulsatile CPB 
can be almost totally normalised by the use of 
pulsatile perfusion. Only 1 out of the 10 patients 
undergoing cardiac surgery?' using pulsatile CPB
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showed a significant ACCR elevation and the mean 
ACCR of the 10 patients in the pulsatile group 
at each sample point did not rise significantly 
above the pre-operative value. The post-bypass 
mean ACCR of 3.1% for this group of patients 
was well below the ACCR level considered to be 
the upper limit of normal (5%). Comparing the 
two groups of patients confirmed that the renal 
excretion of amylase was significantly reduced 
in the pulsatile CPB group during bypass and on 
the first post-operative day. Since there was 
no other significant difference between the two 
groups of patients it may be assumed that the 
norma,lisation of the renal excretion of amylase 
was related to pulsatile perfusion itself. The 
similarity of the mean serum amylase levels in 
the two groups indicates that pulsatile perfusion 
normalises renal excretion by largely preventing 
the reduced amylase reabsorption which has been 
shown to exist following non-pulsatile CPB (77). 
Whether or not this effect of pulsatile perfusion 
is mediated through a protective action on 
pancreatic function remains open to discussion.
The study presented in Chapter 4 demonstrated 
a protective effect on amylase excretion following
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cholecystectomy by the use of Trasylol given 
before, during and after surgery. The results 
suggested that ACCR elevation following chole­
cystectomy was related to pancreatic dysfunction 
and that pancreatic inflammation had been 
diminished by the use of Trasylol prophylactically. 
Ischaemia has been implicated in the aetiology of 
post-bypass pancreatitis (77) and pulsatile 
perfusion may act prophylactically by protecting 
the pancreas through an improvement in its micro- 
circulation.' Warshaw (74) has demonstrated that 
the pancreas is highly vulnerable to ischaemic 
necrosis and has reported a 9% incidence of major 
pancreatic necrosis at autopsy in patients dying 
after hypovo1aemic shock without evidence of 
acute renal tubular necrosis (ATN), compared with 
a 50% incidence of major pancreatic necrosis in
patients dying with concomitant ATN, Studies _____
have shown that pulsatile CPB prevents the 
progressive rise in peripheral resistance which 
occurs with non-pulsatile perfusion thereby 
improving cardiac output and peripheral circulation 
(92,93,94). Improved tissue perfusion during 
pulsatile CPB is reflected in restoration of normal 
pituitary adrenal stress responses (95) and
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reduction in the renin-angiotensin activation 
seen during non-pulsatile CPB (83,84), There 
is therefore good evidence to suggest that 
pulsatile perfusion may protect tissues from 
ischaemic damage during CPB,
If the increase in amylase excretion following 
non-pulsatile CPB were secondary to low molecular 
weight proteinuria following non-specific tissue 
damage, one might expect to find increased amylase 
excretion after operations of a similar magnitude. 
This has not been reported to date and in the 
study where amylase excretion was measured in 
patients undergoing thoracotomy without CPB no 
significant increase in amylase output was observed 
(77), It is possible that non-pulsatile CPB per 
se might result in significant low molecular 
weight proteinuria secondary to non-specific tissue 
breakdown with a resultant increase in amylase 
excretion. Pulsatile CPB may therefore decrease 
amylase excretion by reducing non-specific tissue 
breakdown secondary to ischaemia during bypass. 
There is however no evidence as yet to support 
this hypothesis. The amylase clearance changes 
observed in the non-pulsatile bypass group cannot 
be explained by changes in overall renal function.
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No gross abnormalities in renal function were 
observed and any minor changes would have been 
compensated for by the use of ratio of amylase 
clearance to creatinine clearance (ACCR).
ii) Conclusion
It can be concluded therefore that pulsatile 
flow during CPB can significantly reduce the 
increased renal excretion of amylase, as measured 
by the ACCR, observed during surgery and in the 
early post-operative period following non-pulsatile 
bypass. This finding may indicate that pulsatile 
CPB will protect the pancreas against ischaemic 
damage and hence reduce the incidence of post-bypass 
pancreatitis. Pulsatile bypass is now starting to 
be used commonly in Great Britain and the United 
States and over the next five to seven years it 
should be possible to assess its effect on the
incidence of post-bypass acute pancreatitis. The 
prediction from this ACCR study is that the 
incidence should fall significantly if other factors 
are matched. If this is in fact verified, then it 
will provide substantial evidence that the elevated 
ACCR values observed in this study were related 
to pancreatic inflammation.
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1. INTRODUCTION
In 1972 Professor JW Black and his colleagues 
published the first paper on an H^-receptor antagonist 
named Burimamide and started an explosion of interest 
into this group of compounds (96), Cimetidine (Tagamet) 
was the first of these compounds approved for general 
use in the United Kingdom and to date it has been most 
successful in the treatment of acute duodenal ulceration
(97), Cimetidine has also been used to treat simple
gastric ulceration, peptic oesophagitis, the Zollinger 
Ellison syndrome and upper gastrointestinal haemorrhage, 
both as a prophylaxis and as treatment for established 
bleeding (98),
In 1978 two reports appeared in the”literature which
gave some cause for concern that Cimetidine therapy may 
be causally related to acute pancreatitis. The first 
report was of a patient who developed biochemically 
confirmed acute pancreatitis while receiving oral 
Cimetidine therapy in a dosage of 1 gm/day for duodenal 
ulceration (99), The correlation with Cimetidine therapy 
may well have been spurious, and perhaps the pancreatitis 
was more likely to have been associated with the acute
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duodenal ulceration than with Cimetidine therapy. 
However, at the same time, Joffe and Lee reported 
histologically proven pancreatic inflammation in rats 
receiving Cimetidine to treat experimentally induced 
duodenal ulcers (100).
It was felt that the ACCR would be an appropriate 
screening test to evaluate any relationship between 
Cimetidine therapy and pancreatic inflammation, in 
as much as if the ACCR was not altered significantly 
by Cimetidine therapy a causal relationship with acute 
pancreatitis would be extremely unlikely. It was 
decided to test both acute and chronic administration 
of Cimetidine and this was done by:
1. studying patients receiving Cimetidine 
acutely as a treatment for upper gastro­
intestinal haemorrhage and
2, studying patients attending the peptic ulcer
clinic of the Western Infirmary, Glasgow, 
who were receiving oral Cimetidine regularly 
for duodenal ulceration.
2. PATIENTS AND METHODS
i) The Acute Study
At the time this study was conducted (1980) 
a trial was underway at the Western Infirmary, 
Glasgow, to assess the value of Cimetidine in the
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management of upper gastrointestinal haemorrhage.
All patients admitted to the acute medical receiving 
unit of the Western Infirmary with this diagnosis 
were started on either -
a) Cimetidine - 1.6 gm/day intravenously 
in normal saline or 5% dextrose or
b) a placebo in the same crystalloid 
solutions.
The study was double-blind and the drug packs for 
intravenous and then oral administration were 
identical under the study name of Cimetex.
The code was held centrally and not broken until 
analysis of the data or at the specific request 
of a clinician. Cimetidine therapy was continued 
until definite evidence of recurrent haemorrhage, 
surgery or discharge from hospital. In the Cimetex 
study the site of bleeding was identified in 88% 
of the patients at endoscopy performed within 
24 hours of admission in 90% of cases.
Spot samples (10 ml) of venous blood and 
urine were taken for amylase and creatinine 
estimation within 24 hours of starting Cimetidine 
therapy and again 48 hours later (third day of 
admission) if the patient was still in the unit
and receiving Cimetex, Patients were managed by 
members of the Haematemesis Management Team using 
conventional medical and surgical principles and 
detailed records were kept to facilitate analysis 
of the Cimetex study.
Patients were chosen from the Cimetex study 
for the ACCR study if they fulfilled the following 
criteria;
1, 24 hour ACCR estimation available
2, no past history of pancreatitis
3, no hospital admission in the last five
years
4,' not taking Cimetidine prior to admission
5, no regular medications from the
General Practitioner
6, the site of bleeding defined at endoscopy,
Sixty patients admitted to the Cimetex study 
fulfilled the above criteria and on breaking the 
code after the ACCR study had been completed it 
was found that 32 had received Cimetidine and 28 
had received the placebo.. Assuming effective 
randomisation, the only significant difference 
between the two groups of patients should have 
been the use of Cimetidine and therefore any 
significant difference in the mean ACCR of the two 
groups should have been the result of Cimetidine 
therapy.
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ii) The Chronic Study
Thirty-two out-patients with confirmed 
duodenal ulceration but otherwise in good health 
were studied. No patient had a past history of 
acute or chronic pancreatitis and none had ingested 
alcohol within the 48 hours prior to ACCR estimation, 
The only drugs taken by the patients, apart from 
Cimetidine, were simple antacids in a few cases.
The patients in the study were being treated with 
Cimetidine in a mean daily dose of 863 mg (range 
400-1600 mg) at the time of ACCR estimation and 
had consumed this drug for a mean period of 18 
weeks (range 2-52 weeks). Venous blood and urine 
samples were taken from each patient for amylase 
and creatinine estimation and the ACCR calculated 
using the foanrrula described by Levitt (32),
3. RESULTS
i) The Acute Study
Of the 60 patients studied 32 had received 
Cimetidine acutely while 28 had received the 
placebo,* All 60 patients had suffered an acute 
gastrointestinal haemorrhage and it is therefore 
mandatory to demonstrate that factors which may 
have been detrimental to pancreatic function other 
than Cimetidine were evenly distributed between
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the two groups of patients. Patients with a 
history of pancreatitis, recent significant 
illness and chronic drug ingestion were excluded 
from the study.
Table 18 shows the mean age and sex 
distribution of the 60 patients along with the 
number whose blood alcohol was found to be greater 
than 80 mg percent on admission. Blood alcohol 
estimation was performed routinely as part of 
the Cimetex study. There was no significant 
difference between the two groups in these factors. 
Table 19 shows the source of blood loss defined 
at endoscopy in the two groups of patients. The 
lesions diagnosed were distributed evenly between 
the two groups. Table 20 shows that there was no 
significant difference between the Cimetidine and 
placebo groups with respect to the incidence of 
hypotension, blood loss, further haemorrhage, 
surgery and overall mortality.
Table 21 shows the mean amylase, creatinine 
and ACCR values obtained within 24 hours of 
admission to hospital for the Cimetidine and 
placebo patients. There was no significant 
difference in the mean values of either serum or 
urine amylase although the mean urine amylase
TABLE 18
Nimber, age, sex distribution and admission blood 
alcohol levels in acute study patients.
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Cimetidine Placebo
Number 32 28
Age (yrs) 46 49
Male 22 20
Female 10 8
Admission alcohol 
> 80 mg % 7 6
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TABLE 19
The source of blood loss identified at endoscopy,
Cimetidine Placebo
Acute duodenal ulcer 12 10
Acute posterior 
duodenal ulcer 4 5
Gastritis 8 7
Acute gastric ulcer 6 5
Oesophagitis 4 4
Mallory-Weiss tear 2 2
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TABLE 20
Severity and outcome of upper gastrointestinal haemorrhage.
Cimetidine 
N = 32
Placebo 
N = 28
Admission systolic BP ^ 100 mmHg 3 3
Mean admission Hb (g/1) 9.2 8.7
Mean blood transfusion (units) 3.6 4.2
Further haemorrhage 6 6
Surgery 4 3
Overall mortality % 3.1% 3.6%
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TABLE 21
Amylase, creatinine and ACCR values within 24 hours of 
admission to hospital (mean + s.e.m. ). Unpaired Student's 
t test.
Cimetidine 
N - 32
Placebo 
N = 28
P
Serum amylase iu/1 
Urine amylase iu/l 
Serum creatinine pmol/l 
Urine creatinine yimol/l 
ACCR %
199 + 15 
708 + 100 
97 + 5 
1251 ± 114 
2.9 + 0.3
218 + 22 
600 + 113 
94 ± 3 
1370 ± 196 
1.89 ±  0.2
NS
NS
NS
NS
< 0.025
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value of the Cimetidine group was greater than 
that of the placebo group. The wide scatter of 
urine amylase values however prevented this 
difference reaching statistical significance.
Serum and urine creatinine values were similar 
for both groups but the mean ACCR of patients 
receiving Cimetidine was found to be significantly 
greater than that of patients receiving the 
placebo (p K. 0.025). Four patients (12.5%) 
in the Cimetidine group had an ACCR value greater 
than 5% while this degree of rise was not seen 
in the placebo group*
The significant change in the mean ACCR of 
the Cimetidine group appeared to be short lived 
since when the ACCR was re-estimated in 40 of 
the 60 patients (20 Cimetidine and 20 placebo)
72 hours after admission no significant difference 
in the mean ACCR values was found (Table 22).
The mean ACCR value of the placebo group at 24 
hours (1.89%) and of both groups at 72 hours 
(1.84% Cimetidine: 1,76% placebo) do not differ
statistically from the normal mean ACCR of 1.75% 
derived from earlier studies,
ii) The Chronic Study
The mean ACCR of the 32 outpatients studied
JLH-H-,
TABLE 22
ACCR values 24 and 72 hours after admission to hospital, 
(mean + s.e.m.). Unpaired Student's t test.
Cimetidine Placebo P
24 hr ACCR % 2.9 + 0,3 1.89 + 0.2 <  0.025
72 hr ACCR % 1.84 + 0.2 1.76 + 0.2 NS
ACCR at 24 hr 72 hr for Cimetidine group: p ^ 0.025 
Paired Student's t test.
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was found to be 1.79% + 0.31 s.e.m. which was 
not significantly different from the normal 
mean ACCR of 1.75%.
4. DISCUSSION
On face value the results of this study indicate 
that the intravenous administration of Cimetidine in a 
dosage of 1.6 gm/day may lead to mild pancreatic 
dysfunction which will settle within 72 hours of starting 
the drug and is unlikely to recur on prolonged administr­
ation. If this statement is to hold water then two 
points must be accepted:
1. a significant ACCR elevation is likely to 
be related to pancreatic inflammation and
2. the two groups of patients in the acute 
study were equally matched for risk factors
of pancreatic inflammation excluding Cimetidine 
therapy. -------
The first point is the main theme of this thesis 
and evidence to support this statement has been presented 
in Chapters 3-5 with further evidence to be presented 
in Chapter 7.
i) Matching of the Acute Study Groups
The second point can be answered from the 
data collected in this study which has provided 
evidence heavily in favour of the two acute groups
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being well matched. The age and sex distribution 
of the two acute groups was similar with patients 
slightly younger than the overall population of 
patients admitted with upper gastrointestinal 
haemorrhage. This undoubtedly reflects the 
exclusion clauses in the ACCR study which biased 
against the elderly and chronic sick. Alcohol 
ingestion may certainly induce an attack of acute 
pancreatitis and it was therefore gratifying to 
find that the consumption of alcohol just prior 
to admission was evenly distributed between the 
two groups in the acute study. In the chronic 
study all patients denied alcohol intake in the 
48 hours prior to ACCR estimation.
The pathologies resulting in upper gastro­
intestinal haemorrhage were found to be evenly 
distributed between the two acute groups of 
patients. Only patients in whom a confident 
diagnosis of the source of blood loss had been 
made at endoscopy were accepted for the ACCR 
study. The incidence of posterior duodenal 
ulceration, which may be directly related to 
acute pancreatitis, was similar in both groups.
No malignant conditions were included in the study 
and in the seven patients who came to surgery the 
endoscopic diagnosis was confirmed in all cases.
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Warshaw has documented that acute pancreatitis 
can be associated with hypovolaemic shock especially 
in the presence of acute tubular necrosis of the 
kidneys (74). In the acute part of this study 
the incidence of shock on admission was 9% for the 
Cimetidine group and 11% for the placebo group.
This amounted to six patients in all, none of whom 
developed acute tubular necrosis. Warshaw*s 
incidence of acute pancreatitis in this situation 
was only 9% which means that statistically 11 
patients in this study would need to have been 
shocked before one case of acute pancreatitis 
would be expected. The mean admission haemoglobin 
and the mean blood transfusion required by each 
group of patients were similar, indicating similar 
blood loss in both groups. The incidence of 
further haemorrhage and surgery and the overall 
mortality were again similar for both groups of 
patients. The low overall mortality for a group 
of patients with acute upper gastrointestinal 
haemorrhage reflects the patient selection for 
this study,
ii) ACCR Results and Implications
The mean ACCR of the acute Cimetidine group 
was found to be significantly higher than that of 
the placebo group within 24 hours of starting
Cimetidine therapy. The mean ACCR of the 
Cimetidine group at this time (2.9%) was not 
in the same range as the mean value for patients 
with acute pancreatitis (5%) described in Chapter 
3, Only 4 out of 32 patients in the Cimetidine 
group had an ACCR greater than 5% on the first 
sample and this change is certainly less marked 
than that seen after cholecystectomy or cardio­
pulmonary bypass using the non-pulsatile pump.
In this study the placebo group, on the other 
hand, had a normal mean ACCR value on the first 
sample (less than 24 hours after admission) and 
no patient in this group had an ACCR value greater 
than 5%, It is therefore likely that the ACCR 
change observed in patients received Cimetidine 
for less than 24 hours is meaningful and may well 
represent an effect of Cimetidine on pancreatic 
function. It may well be that in the acute phase 
of an illness such as upper gastrointestinal 
haemorrhage the pancreas is more susceptible to 
daiïiage by an agent such as Cimetidine and this 
may well be the point demonstrated by this study.
At 72 hours after admission and on chronic 
Cimetidine therapy there was no evidence of any 
effect of Cimetidine on the ACCR. This indicates
that any effects of Cimetidine on pancreatic 
function only act in the acute phase of 
administration and may well be related to any 
underlying debility at the time of starting 
Cimetidine administration. No patient in the 
Cimetidine group of this study developed acute 
pancreatitis as defined by serum amylase values, 
and from this study it would appear that the 
risk of developing acute pancreatitis as a result 
of Cimetidine therapy is a theoretical rather 
than practical possibility. The possibility 
of acute pancreatitis at the start of Cimetidine 
therapy should be borne in mind, however, in 
patients with a past history of acute pancreatitis 
and patients with acute debilitating conditions 
receiving the drug.
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C H A P T E R  S E V E N
THE PROGNOSTIC VALUE OF THE AMYLASE CREATININE 
CLEARANCE RATIO IN ACUTE PANCREATITIS AND ITS 
RELATIONSHIP TO ENDOTOXAEMIA AND COMPLEMENT ACTIVATION
INTRODUCTION
i) Prognostic Factors in Acute Pancreatitis
An MRC Multicentre study involving 10 centres 
in Great Britain and Northern Ireland, including 
the Western Infirmary, Glasgow, has recently 
documented an overall mortality of 11% in acute 
pancreatitis as defined in this thesis (62).
During the decade 1960-1969 the mortality from 
acute pancreatitis in a single Glasgow hospital 
was recorded as 18.9% (47). From 1971 to 1974 
the mortality from acute pancreatitis in the same 
Glasgow hospital fell to 11% in agreement with the
MRC figures obtained two years later (101). This _
reduction in mortality was achieved by careful 
conservative management of acute pancreatitis and 
by the early recognition and treatment of the 
known complications of the disease* It is 
unlikely that the existing mortality rate in 
acute pancreatitis will be significantly reduced 
further until a means of specifically inhibiting 
pancreatic inflammation is discovered. In the
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meantime some workers have attempted to identify 
those patients who do badly at an early stage 
in their illness in an attempt to be more 
aggressive with their initial management in order 
to "pre-treat* anticipated complications (102,103, 
104,105,106). Ranson and his group have used 
11 objective findings which correlated with the 
occurrence of serious illness or death (103), 
while Imrie in Glasgow has employed nine objective 
findings obtained within the first 48 hours of 
admission to predict outcome in acute pancreatitis 
(105). Neither of these workers has included the 
ACCR in their prognostic evaluation.
The debate in the literature since 1974 
concerning the ACCR has almost exclusively pertained 
to the tests relationship to pancreatic inflammation 
and the mechanisms which may produce the increase 
in the renal clearance of amylase. No publication, 
to date has prospectively examined the prognostic 
role of the ACCR in acute pancreatitis. This 
seemed to be an omission in the evaluation of the 
ACCR, especially in view of the findings presented 
in this thesis suggesting that the ACCR may be a 
very sensitive index of pancreatic inflammation.
In only one paper has a possible prognostic role 
for the ACCR been suggested with some evidence
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to back up the claim. In 1979 Van Hee and Hubens 
published a study of 18 patients with acute 
pancreatitis as defined in this thesis, 53 
patients with intra abdominal diseases apart 
from acute pancreatitis and 80 control patients 
(107). The mean ACCR for the group with acute 
pancreatitis was 7.4% as against 2,4% for the 
control patients (p K. O.OOl). Twenty-six patients 
with peripancreatic disorders, i.e. common duct 
stones, gastric cancer and peptic ulcers, were 
selected from the group of 63 patients with 
intra abdominal diseases other than acute 
pancreatitis. At operation 85% of these 26 patients 
were noted to have a mild form of oedematous 
pancreatitis and the mean ACCR of all 26 on 
admission was found to be significantly elevated 
at 4.1%. This level was significantly lower,
however, than that for those patients diagnosed_____
as having acute pancreatitis as their primary 
disorder. These observations led the authors 
to suggest that the extent of the rise in the 
ACCR may help to discriminate between mild and 
severe attacks of acute pancreatitis.
The aim of this study was therefore to examine 
the role of the ACCR as a prognostic index in acute 
pancreatitis in a prospective study using death
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and Imrie*s prognostic factors to judge the 
severity of each attack of acute pancreatitis.
ii) Endotoxaemia and Acute Pancreatitis
In order to maximise the returns from a 
prospective study of acute pancreatitis it was 
decided to combine the ACCR study with a study 
of endotoxaemia and complement activation in 
acute pancreatitis. In 1974 it was reported that 
three patients with peritonitis due to acute 
pancreatitis had endotoxin detected in their 
circulation only when they had peritonitis and 
not when the disease had resolved (108). Cuevas 
et al (109) have shown that in experimental sterile 
peritonitis in rabbits there is a release of 
endotoxin from the gut into the systemic circulation 
and it has been proposed that this may be the 
source of endotoxin in patients with acute 
pancreatitis (108,110). Endotoxaemia could itself 
explain some of the systemic complications of 
acute pancreatitis, i.e. shock lung, disseminated 
intravascular coagulation and renal failure (110, 
111).
iii) Complement Activation in Acute Pancreatitis 
There is also evidence of complement
catabolism in acute pancreatitis (112) and
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experimental animal work has suggested that 
complement depleted animals develop less severe 
pancreatitis (113,114). Recently systemic 
activation of complement has been implicated in 
the development of shock lung (115) which may 
help to explain the hypoxia of acute pancreatitis. 
Since endotoxin is kno\m to activate complement 
through the alternative pathway (116) it seemed 
possible that endotoxaemia, resulting from the 
peritonitis associated with acute pancreatitis, 
may be instrumental in activating complement in 
this disease. The aims of this part of the study 
were to test this hypothesis and to see whether 
the presence of endotoxaemia and the degree of 
complement activation correlated with the severity 
and mortality of acute pancreatitis. This study 
also allowed for the evaluation of the relationship, 
if any, between the ACCR, endotoxaemia and complement 
activation. Only the aspects of the endotoxin and 
complement results that relate to the ACCR will be 
presented in detail in this thesis. The remainder 
of the work on endotoxaemia and complement activation 
will be referred to where necessary but not presented 
in depth as it is judged to be outwith the remit 
of this thesis.
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2, PATIENTS AND METHODS
Thirty-one patients admitted to the acute surgical 
receiving unit of the Western Infirmary, Glasgow, with 
a diagnosis of acute pancreatitis were accepted for the 
study. The diagnosis of acute pancreatitis was made 
in one patient at laparotomy, while in the other 30 
the diagnosis was made using the criteria described 
in Chapter 3. No cases of post-operative or post- 
traumatic acute pancreatitis were included and where 
possible the patients progress was followed until a 
cause for the attack of acute pancreatitis was identified.
Tlie severity of each attack of acute pancreatitis 
was assessed using Imrie * s criteria (105) which had 
been evolved from studies on patients with acute 
pancreatitis in a Glasgow teaching hospital. A patient 
was judged to have potentially severe acute pancreatitis 
if, within the first 48 hours of admission, three or 
more of the following nine factors were present;
1. Pa02 < 60 mmHg
2. Serum albumin ^ 32 g/l
3. Serum calcium ^ 2.0 ramol/l
4. W.B.C. >  15 X 10^/1
5. SGOT/PT > 100 u/1
6. LDH > 600 u/1
7. Plasma glucose > 10 mmol/1
8. Blood urea > 16 mmol/l
9. Age y 55 years.
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The ACCR was estimated within 48 hours of admission 
using samples of venous blood and urine analysed for 
amylase and creatinine as previously described. Venous 
blood was assessed daily for the presence of endotoxin 
and blood cultures were carried out routinely in 
conjunction with this estimation. The complement 
components C^, C^, factor B, C^d and complement 
haemolytic activity, as measured by CH^^ and alternative 
pathway CH^^, were estimated daily for up to five days. 
Endotoxaemia was assessed using the limulus lysate 
technique and the reactions were graded from 0 (no 
endotoxin) to 3 (marked endotoxin). The technique 
used by Dr. Christine McCartney in the Western Infirmary 
and the techniques used by Dr. Keith Whaley to estimate 
the complement components have been fully described 
recently in the literature (117).
The complement system may be activated through
either the classical pathway, through which Trypsin____
works, or the alternative pathway through which 
endotoxin acts (Figure 17). Once activated, complement, 
as measured by C^, is broken dovjn into a number of 
degradation products including C^d. Some of these 
products are biologically active and are responsible 
for the systemic effects of complement activation. 
Complement activation has been assessed in this study
FIGURE 17
The complement system,
Classical Pathway Alternative Pathway
(endotoxin)(trypsin)
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C^d
by using the p—  ratio. As complement activation 
C^d
increases the —  ratio will rise due to the breakdo^fn
3
of and increase of its degradation product C^d.
Whether it is the classical pathway or the alternative 
pathway or both that has caused complement activation 
can be determined by measuring markers for each pathway.
and will fall if the classical pathway is
activated while factor B and alternative pathway 
will fall if the alternative pathway is activated.
All these components were measured in this study to 
allow a comprehensive assessment of the functioning 
of the complement system in acute pancreatitis,
3. RESULTS
i) Patient Details
There were 31 patients with acute pancreatitis 
in this study and of these 8 were predicted to
have potentially severe disease by having a -----
positive factor count of ^  3 within 48 hours of 
admission to hospital. This left 23 patients 
with a prognostic factor count of less than 3 and 
these two groups were compared in an attempt to 
relate the admission ACCR to the predicted severity 
of each attack of acute pancreatitis. The mean age 
of the two groups of patients was similar (Table 23)
IbU,
TABLE 23
Comparison of patient details based on predicted severity 
of acute pancreatitis.
Factor count ^  48 hrs
< 3
Number 8 23
Mean Age (yrs) 54 51
Males/females 0.6 1.9
Gallstones % 63 35
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but there were more females in the potentially 
severe group than in the mild to moderate group 
(factor count 3). This difference can be 
explained by the 63% incidence of gallstone 
induced acute pancreatitis in the potentially 
severe group compared to 35% in the mild to 
moderate group which contained more alcohol 
induced attacks (Table 23).
No attempt was made to assess the morbidity 
of each attack of acute pancreatitis other than 
through the purely quantitative biochemical and 
haematological measurements made (Table 24). 
Subjective factors such as severity of pain and 
frequency of bowel sounds were not assessed, 
while management dependent variables such as 
duration of nasogastric suction and total stay 
in hospital were not recorded because patients 
with acute pancreatitis managed by all the surgical" 
teams in the Western Infirmary, Glasgow, were 
included in the study. There was therefore no 
absolute uniformity of management in this study. 
Significant hypoxia (PaO^ ^ 60 mmHg) occurred in 
5 patients in the potentially severe group and 3 
of these patients died. This complication was 
not noted in the mild to moderate group. Five 
patients in the potentially severe group only
TABLE 24
Comparison of morbidity and mortality based on predicted 
severity of acute pancreatitis.
Factor count 48 hrs
> 3 < 3
Significant hypoxia 5 0
Intravascular coagulation 5 0
Renal failure 3 0
Mortality % 25 0
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were found to have coagulation abnormalities
in that either their platelet count fell to less 
than 50,000/mm or serum fibrin degradation 
products were raised above 40 mm/1.' Only 3 
patients developed renal failure and all died.
The mortality in the potentially severe group 
was 25% compared with no deaths in patients judged 
to have only mild or moderate disease (factor 
count ^ 3). Out of 38 attacks of acute pancreatitis 
studied in the project as a whole, 11 patients 
were judged to have potentially severe disease 
using the factor count and 4 of these died (36%), 
with no deaths in the remaining 27 patients judged 
to have mild to moderate disease. These findings 
support the use of the factor count as a predictor 
of severity in acute pancreatitis. The ACCR values 
were only available in 31 of the 38 attacks of
acute pancreatitis mentioned above and therefore-----
only these patients are reported in detail.
The mean values of three of the four estimations 
used to calculate the ACCR within 48 hours of 
admission are shown in Table 25 along %fith the 
mean values for blood urea. The values for the 
patients with predicted severe acute pancreatitis 
are compared to those of the patients with predicted 
mild to moderate attacks. As expected there was
TABLE 25
Comparison of biochemical tests based on predicted 
severity of acute pancreatitis - mean + s.e.m. 
Unpaired Student’s t test.
Factor Count ^  48 hrs
P
> 3 <  3
Serum amylase i.u./l 5089 + 1165 4834 + 906 N.S.
Urine amylase i*u./l 8393 + 1614 8753 + 1307 N.S.
Serum creatinine yumol/l 117 + 14 91 ± 3 N.S.
Blood urea mmol/l 7.7 + 1.8 4.7 + 0.4 N.S.
ACCR % 10.1 + 0.9 5.7 + 0.3 < 0.001
no significant difference between the serum and 
urine amylase values for each group. It is 
generally accepted that although diagnostic of 
acute pancreatitis in the majority of cases, 
the serum amylase level per se has no prognostic 
value (14). The mean values for both serum 
creatinine and blood urea were raised in the 
potentially severe group of patients although 
the differences were not statistically significant. 
In no patient was the level of creatinine in the 
serum on admission such that an alteration in the 
ACCR on account of impaired renal function would 
have been expected,
ii) ACCR Results
The mean ACCR of patients predicted to have 
severe attacks of acute pancreatitis using the 
factor count was found to be significantly greater
than the mean value of the 23 patients predicted--
to have mild to moderate attacks (Table 25).
The individual ACCR values obtained from all 31 
patients within 48 hours of admission are sho^m 
in Figure 18. In this figure the patients have 
been divided into those with potentially mild 
acute pancreatitis (factor count 2), those 
with potentially moderate acute pancreatitis 
(factor count = 2) and those with potentially
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Figure 18« ACCR values in mild ( <(, 2)
moderate (2) and severe ( ^ 2) 
acute pancreatitis^
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severe acute pancreatitis (factor count )> 2).
It can be seen from the scattergram that the 
distribution of ACCR values in the first two groups 
of patients (mild and moderate) is similar and 
these two groups have been combined for further 
analysis of results. The ACCR values of patients 
with a factor count of > 2 are higher than the 
other two groups with only one patient in the 
potentially severe group having an ACCR value 
lower than the highest value in the other two 
groups. Both patients who died in the study were 
identified as having potentially severe acute 
pancreatitis by the factor count and both had 
ACCR values over 10% within 48 hours of admission. 
These represented two of the three highest ACCR 
values recorded in this study. Only 2 of the 31 
patients had an ACCR of less than 5% within 48 
hours of admission and this represents a 94% 
diagnostic accuracy which is exactly the same 
figure that was obtained in the first study 
presented in Chapter 3,
iii) Endotoxin Results
A patient was considered to have significant 
endotoxaemia when two consecutive venous blood 
samples were positive for endotoxin on limulus 
lysate assay. Twenty-one patients in this study
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had both endotoxin and ACCR estimated and of 
these 10 (40%) were found to be endotoxin positive 
as defined above. The mean ACCR within 48 hours 
of admission for the endotoxin positive patients 
was found to be 6.85% compared to 6.71% for the 
endotoxin negative patients. There is no significant 
difference between these values and it therefore 
appears that the ACCR is not influenced by the 
presence or absence of endotoxin in the blood 
during an attack of acute pancreatitis.
iv) Complement Results
The relationship between the ACCR and the 
activity of the complement system within 48 hours 
of admission to hospital with an attack of acute 
pancreatitis was examined by plotting the ACCR 
against the ^3^ ratio for each patient. The result
S
is shown in Figure 19 and a significant positive----
correlation between the two factors is demonstrated
(p ^ 0.001). As the ^3^ ratio increases, indicating
^3
increasing complement activation, so too does the 
ACCR. The next step was to test this correlation 
of the ACCR with complement activity against the 
activation pathways for the complement system to 
see if the ACCR correlated with classical or
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Figure 19, Relationship between total complement 
activation and the ACCR^
Linear regression^
Correlation coefficient “ 0.85 : p <, 0.001
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alternative pathway activity or both. Figures
20 and 21 show a highly significant negative
correlation between the ACCR and both C. and4
CH^Q, two markers of classical pathway activity.
As these factors fall, indicating increasing 
consumption and activation of the classical 
pathway, so the ACCR rises. When the corresponding 
markers for the alternative pathway (factor B and 
alternative pathway CH^^) were plotted against 
the ACCR, no significant correlation was found 
(Figure 22 and 23). It therefore appears that 
in acute pancreatitis the ACCR is positively 
related to the activation of the complement system 
via the classical pathway only.
4. DISCUSSION
i) Prognostic Factors
The prognostic factor count used in this 
study of patients with acute pancreatitis was 100% 
reliable with respect to mortality and accurate 
in the prediction of the significant short term 
complications of the disease. Professor Ranson 
from New York described 11 prognostic factors in 
acute pancreatitis and stated that to have three 
or more of these factors present within 48 hours 
of admission indicated potentially severe acute
C4
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Figure 20, Relationship between classical pathway 
complement activation (C4) and the 
ACCR.
Linear regression.
Correlation coefficient = -0.73 : p 0.001
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Figure 21. Relationship between classical pathway 
complement activation (CH50) and the 
ACCR.
Linear regression*
Correlation coefficient = -0.79 : p ^ 0.001
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Figure 22. Relationship between alternative pathway 
complement activation (Factor B) and the 
ACCR.
Linear regression.
Correlation coefficient = «0.2
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complement activation (A.Po CH50) and the 
ACCR,
Linear regression.
Correlation coefficient - -0,28
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pancreatitis. He reported 100 cases of acute 
pancreatitis of which 21 fell into the potentially 
severe group. These patients had a mortality of 
62% and a serious morbidity of 95% in the 
survivors compared with 3% and 12% respectively 
with patients with less than three prognostic 
factors (103). Imrie has assessed the value of 
these factors using the results of his studies 
of patients with acute pancreatitis in Glasgow 
(105). As a result of this he discarded -
1. a haematocrit decrease of y 10% in 48 
hours
2. a base deficit of y 4 mequiv/l and
■ 3, an estimated fluid sequestration of 
over 6,1 in 48 hours from Ranson's 
criteria and added «
a, a serum albumin of 32 g/l, giving nine 
factors which did not require to be 
repeated for full interpretation.
These factors were used in this study since 
it was felt to be more appropriate to use data 
derived in Glasgow for a Glasgow study. Retrospective 
analysis of the severity of each attack of acute 
pancreatitis in this study (Table 24) shows that 
the factor count used gave art accurate prediction
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of both mortality and serious morbidity if the 
presence of three or more prognostic factors 
was taken to indicate the likelihood of a severe 
attack of acute pancreatitis. It seems that the 
use of this discriminant as a means of expressing 
the severity of an attack of acute pancreatitis 
is justified since its predictive accuracy is 
excellent. It was therefore used in the study 
to assess the prognostic role of the ACCR in 
acute pancreatitis.
ii) ACCR Data
All but 2 of the 31 patients diagnosed as 
having acute pancreatitis in this study had an 
admission ACCR value ]> 5%, the upper limit of 
normal defined in Chapter 4, The 8 patients 
with three or more prognostic factors within 
48 hours of admission, however, had a significantly 
higher ACCR (p <,0.001) than the 23 patients whose 
factor count was less than 3. The difference 
between the two groups of patients was striking 
with only 1 3 factor patient overlapping with
the other group. The results of this study 
suggest that in acute pancreatitis an ACCR value 
within 48 hours of admission does have a prognostic 
value with a direct relationship between the
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probable severity of the acute attack and the 
ACCR result. Moreover, the results of this study 
suggest that a patient with acute pancreatitis 
who has an ACCR ^  10% within 48 hours of admission 
to hospital is extremely likely to suffer from a 
severe attack of the disease.
iii) Endotoxin Data
Forty percent of patients with acute 
pancreatitis in this study were discovered to have 
significant endotoxaemia as defined above at some 
stage during the first five days in hospital, 
Endotoxaemia was not related to the insertion of 
an indwelling urethral catheter and a septic 
source was only found in two patients. Significant 
endotoxaemia per se was found to have no effect 
on the ACCR which was the same for both endotoxin 
positive and endotoxin negative patients. This
finding is relevant since Dr. Levitt has suggested 
that endotoxaemia may be the cause of the impaired 
renal tubular reabsorption of amylase seen in 
acute pancreatitis (personal communication).
iv) Complement Data
The full study showed that some degree of
increased complement activation was universal
in patients with acute pancreatitis. The mean
^3^ level on day 1 was 12.47 x 10“ ,^ with an 
C„
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upper limit of normal of 6,03 x 10  ^ (p <, 0.001). 
Complement activation was found to be related 
to the predicted severity of the disease and 
was most marked in the patients who died. There 
was evidence of both classical and alternative 
pathway activation of the complement system, but 
in the potentially severe group, with the greatest 
incidence of significant endotoxaemia, alternative 
pathway activation was predominant.
The ACCR was found to be directly related 
to complement activation and this relationship 
was found to be statistically highly significant.
This correlation supports the evidence that the 
ACCR may be of prognostic value since complement 
activation was itself found to be related to 
severity in acute pancreatitis. The ACCR was 
found to correlate specifically with complement 
activation via the classical pathway and not 
the alternative pathway. This suggests strongly 
that the relationship between the ACCR and complement 
activation is indirect rather than direct. It is 
probable that both the ACCR and the complement 
system are influenced in acute pancreatitis by a 
third factor rather than complement activation 
directly influencing the ACCR. If that were the 
case one would have expected the ACCR to correlate
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with both classical and alternative pathway 
activation instead of classical pathway activation 
alone,’ This finding suggests that some other 
factor, which stimulates complement activation 
through the classical pathway, also acts to alter 
the ACCR in acute pancreatitis. The most likely 
candidate for this role in acute pancreatitis is 
Trypsin which is known to activate complement 
through the classical pathway (118,119). Thus 
Trypsin, and perhaps other proteolytic pancreatic 
enzymes, may be the link in the chain and explain 
why the ACCR appears to be related to complement 
activation in acute pancreatitis. The evidence 
relating an elevated ACCR to pancreatic inflammation 
has therefore been strengthened by this study.
For the first time there is some evidence that 
Trypsin and possibly other proteolytic enzymes
from the pancreas are directly responsible for -----
producing the renal tubular phase of the increase 
in anylase excretion seen in acute pancreatitis.
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DISCUSSION AND CONCLUSIONS
1. SUMMARY OF MAIN FINDINGS
The studies presented in this thesis have produced 
both conclusive findings and findings which are open 
to interpretation and discussion. The conclusive 
findings are listed as follows:
1. The ACCR is a simple test to perform in an 
acute or elective situation and the result 
can be available within an hour of taking 
the venous blood and urine samples.
2. The ACCR was found to be an accurate 
diagnostic test for acute pancreatitis in 
48 patients diagnosed by hyperamylasaemia 
or laparotomy. Ninety-four percent of 
these patients had an ACCR value above the 
appropriate upper limit of normal within— -—  
48 hours of admission to hospital.
3. The ACCR was significantly elevated in 7 
out of 48 patients with confirmed acute 
pancreatitis who had either normal serum 
amylase levels or levels below the minimum 
considered diagnostic for acute pancreatitis 
at the time of testing.
±oz.
4. The ACCR, estimated within 48 hours of
admission to hospital, has been shown to 
be directly related to the severity of 
an attack of acute pancreatitis.
5. The ACCR was found to be significantly
correlated with the activation of complement 
via the classical pathway in acute pancreatitis
6. The ACCR was not significantly elevated in
267 patients admitted to hospital with acute 
or chronic conditions outwith the pancreas 
despite significantly elevated mean serum 
and urine amylase levels in 35 patients
with acute intra-abdominal diseases excluding 
acute pancreatitis.
7. Significant ACCR elevation was documented 
following cholecystectomy, cardiac surgery 
using cardiopulmonary bypass and the acute 
administration of Cimetidine intravenously 
in patients with upper gastrointestinal 
haemorrhage.
8. The significant ACCR elevation following 
cholecystectomy was reduced by Trasylol 
infusion before, during and after surgery.
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9, The significant ACCR elevation following 
non-pulsatile cardiopulmonary bypass was 
reduced by using pulsatile cardiopulmonary 
bypass.
2. SUMMARY OF MAIN DISCUSSION POINTS
The following points arising from this work are 
not clear-cut conclusions and require either support 
from the literature, confirmation from repeat studies 
or further evaluation through a different approach.
1. Is a significantly elevated ACCR in the
absence of hyperamylasaemia specific for 
acute pancreatitis?
2. Is the significant ACCR elevation following
cholecystectomy, cardiopulmonary bypass 
and acute Cimetidine therapy related to 
pancreatic inflammation?
3. Is the relationship between the ACCR and 
the complement system in acute pancreatitis 
secondary to Trypsin activity?
3. DISCUSSION
Up to 1966 the literature relating to the ACCR 
referred to in Chapter 2 was generally favourable, 
with authors regarding a significantly elevated ACCR 
as an accurate index of acute pancreatic inflammation
184.
which might possibly be specific for that disease.
Since then the picture has become more confusing.
There have been favourable reports on the diagnostic 
accuracy of the ACCR in acute pancreatitis from Great 
Britain (120,121), Sweden (122), Belgium (107),
Up SoA, (123,124,125) and China (126), The upper limit 
of normal for the ACCR in these studies varied from 
3% to 5.3% and Levitt has suggested that the results 
of amylase clearance measurements vary with the 
technique of amylase assay employed (127), One must 
therefore know the normal ACCR for the technique employed 
in one * s own laboratory in order to make a meaningful 
interpretation of the measurement on a patient, . This 
is illustrated in this thesis by the difference between 
the upper limit of normal for the ACCR obtained in the 
study presented in Chapter 3 and the subsequent studies 
(3% and 5% respectively). This difference is explained 
by the addition of bovine serum albumin to the Phadebas 
test kit used in all but the first study. This addition 
increases the sensitivity of the Phadebas test for 
amylase, especially in the urine, and therefore tends 
to slightly increase the value of the ACCR for any 
one specimen (45, 128).
The specificity of a raised ACCR for acute 
pancreatitis has been challenged in some studies.
Marten et al, from London, noted significant ACCR 
elevation in patients with diabetic ketoacidosis, 
fulminant alcoholic liver disease and advanced 
renal failure (121), They were however unable to 
exclude acute pancreatitis in all these cases. The 
paper by Berger et al (44), mentioned in Chapter 2, 
suggesting that the ACCR was significantly raised in 
2 out of 5 patients with an acute perforated duodenal 
ulcer was soon followed by a paper from West Germany 
questioning the value of the ACCR in acute pancreatitis 
(129), The West German authors studied 190 patients 
with hyperamylasaemia with the aim of documenting 
the incidence of macroamylasaemia and used the ACCR 
among other tests to screen for this. Fifty-six 
patients were retrospectively judged to have acute 
or chronic pancreatitis, 27 patients were suspected 
but not proven to have acute pancreatitis and in 107
patients there was no evidence of pancreatic disease____
apart from an elevated serum amylase. This 
classification of the patients in this study is clearly 
unacceptable since no criteria for the diagnosis or 
exclusion of pancreatitis in the presence of hyper­
amylasaemia was given and the number of patients 
without pancreatitis in the presence of hyperamylasaemia 
was very high. No control group was studied and no 
local normal range for the ACCR established, the
JL5D,
authors accepting a value of K  4% as normal.
Nineteen out of 46 patients with acute pancreatitis 
had an ACCR "K. 4% while 48 out of the 134 patients 
in the non-pancreatitis groups had an ACCR ^4%.
However 27 patients in the non-pancreatitis groups 
were suspected of having acute pancreatitis and they 
were not excluded from these results. Although these 
results raised doubts about the accuracy and specificity 
of the ACCR in the diagnosis of acute pancreatitis, 
the study itself was criticised in several areas 
and the relevance of the results questioned (M Levitt - 
personal communication).
In 1977 Lankisch and his co-workers from Sweden 
published a paper reporting a normal ACCR in 11 out 
of 33 patients diagnosed as having acute pancreatitis 
by hyperamylasaemia (130), The mortality for this 
group was high at 24% and acute pancreatitis was 
confirmed at all seven post-mortem examinations. The 
mean ACCR in their laboratory for 21 healthy volunteers 
was 1,8% + 1,0 2S,D, This gave an upper limit of 
normal for the ACCR in the author’s hospital of 3%, 
as found in the study presented in Chapter 3, For 
no good reason, however, the authors chose 5,3% as 
their upper limit of normal and, based on this figure, 
the ACCR was normal in 36% of the patients with acute
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pancreatitis and hyperamylasaemia on their first day 
of admission. If an ACCR of over 3% had been accepted 
as abnormal for this study then 88% of patients with 
acute pancreatitis would have had an abnormal value 
on admission, including 5 patients with acute 
pancreatitis without hyperamylasaemia diagnosed at 
laparotomy. This totally changes the message from 
the study and emphasises the importance of establishing
and using a normal range for the ACCR in one’s otvn
hospital.
In 1978 Farrar and Calkins from Kansas City 
reported that in 29 male patients with alcohol induced 
acute pancreatitis diagnosed by hyperamylasaemia the 
ACCR was only significantly elevated ( > 5,3%) in 
59% (131), The authors were unable to explain the 
discrepancy between their results and others regarding 
the ACCR, They stated that, apart from one case who
died, all their patients had mild acute pancreatitis_...__...
with no evidence of shock or renal failure. They 
also admit that they cannot prove that their patients 
had acute pancreatitis since there was no biopsy or 
autopsy evidence of the disease. The results in 
this thesis support a relationship between ACCR 
elevation and the severity of an attack of established 
acute pancreatitis. On the other hand significant 
elevations of the ACCR have been recorded in studies
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In this thesis when only sub-clinical pancreatic 
inflammation was presumed to be present. Warshaw 
has shown that the ACCR may discriminate between 
pancreatic and non-pancreatic hyperamylasaemia (35), 
and it may be that in Farrer and Calkins study of 
heavy alcohol drinkers with apparent mild acute 
pancreatitis some of the patients with normal ACCR 
values may have had other causes for their hyper­
amylasaemia.
The concensus of opinion in the literature to 
date remains favourable to the concept of the ACCR 
as a useful diagnostic test in patients suspected of 
having acute pancreatitis. This has been supported 
in two studies in this thesis with a 94% accuracy 
for the ACCR in reaching a diagnosis of acute 
pancreatitis in 48 patients of whom 7 did not have 
significant hyperamylasaemia. It has been suggested 
that the ACCR may be most useful as a diagnostic test 
for acute pancreatitis in patients with high serum 
levels of amylase of uncertain origin (127). A low 
ACCR strongly supports a non-pancreatic cause for 
the hyperamylasaemia,. whereas a high ACCR indicates 
a strong probability of the presence of acute pancreatitis, 
The interpretation of an abnormal ACCR in the presence 
of a normal serum amylase is much more difficult and 
there appears to be no fixed opinions in the literature
189.
regarding this. Can mild, resolving or sub-clinical 
pancreatic inflammation be detected by an elevated 
ACCR and does an elevated ACCR in the absence of 
hyperamylasaemia always indicate pancreatic inflammation? 
These are the crutial questions that the work presented 
in this thesis has gone some way towards answering.
There is no doubt that an elevated ACCR commonly 
occurs in mild or resolving acute pancreatitis in the 
absence of hyperamylasaemia. The delay in ACCR values 
returning to normal compared to serum amylase following 
an attack of acute pancreatitis was noted in the first 
ACCR paper in 1969 (32) and confirmed in the patients 
studied and presented in Chapters 3 and 1 in this 
thesis. This suggests that the ACCR is a sensitive 
test for pancreatic inflammation but may in fact only 
demonstrate that the renal tubular changes induced 
by a clinically evident attack of acute pancreatitis 
are slow to resolve. If this were the case then the 
ACCR would not necessarily be a sensitive test for 
mild or sub-clinical pancreatic inflammation. The 
most convincing direct evidence in the literature 
supporting the former view that the ACCR is a 
sensitive test for pancreatic inflammation comes from 
Van Hee (107), His group studied 25 patients with 
acute peripancreatic disorders who underwent emergency 
laparotomy and found a mild form of oedematous
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pancreatitis, previously unsuspected clinically, in 
85% of these patients. The mean ACCR value for this 
group on admission (4.1%) was significantly higher 
than for patients with acute intra-abdominal diseases 
not involving the pancreas (2.6%) and significantly 
lower than for patients diagnosed conventionally as 
having acute pancreatitis (7.4%). This study 
indicates that significant ACCR changes in the absence 
of hyperamylasaemia can reflect unsuspected pancreatic 
inflammation and suggests that the degree of ACCR 
elevation may reflect the severity of the disease 
process. In 31 patients with acute pancreatitis in 
this study (Chapter 7), the ACCR almost completely 
differentiated between 8 patients with potentially 
severe disease and 23 patients with only mild to 
moderate disease. An ACCR ^  10% always occurred 
in patients with severe disease in whom two out of 
three died. Seven of the patients in the two studies 
of acute pancreatitis in this thesis had a serum 
amylase value below the diagnostic level for the 
disease at the time of ACCR estimation within 24 
hours of admission. Tlie ACCR, however, was significantly 
elevated in all 7 and the diagnosis of acute 
pancreatitis was reached independently by laparotomy 
in 3 cases and an initial serum amylase value above
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the lower diagnostic level in 4. The 3 cases in 
whom acute pancreatitis was independently diagnosed 
in the presence of a significantly elevated ACCR and 
a normal serum amylase level again demonstrate that 
the ACCR can detect pancreatic inflammation in the 
absence of significant hyperamylasaemia. It is 
probable that in these cases the serum amylase had 
fallen below the diagnostic level for acute pancreatitis 
prior to admission to hospital and it was the prolonged 
effect of acute pancreatitis on amylase excretion which 
allowed the ACCR to confirm the diagnosis. In Van 
Hee’s patients, on the other hand, a mild and unsuspected 
pancreatitis was demonstrated and correlated with a 
significant increase in ACCR (107). There was no 
suggestion that the pancreatitis observed in these 
patients was resolving from a more severe attack which 
had been misdiagnosed.
The ACCR was found to be significantly elevated ----
in this thesis in patients following cholecystectomy 
and during and after cardiac surgery performed using 
non-pulsatile cardiopulmonary bypass. These basic 
observations have been made by other workers both 
before and after the work presented in this thesis 
(55,56,57,58,59,76,77,132,133,134). In the studies 
presented in Chapters 4 and 5 there were only 2 cases
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of acute pancreatitis diagnosed by hyperamylasaemia 
out of 71 patients studied and this is in agreement 
with the general experience in the literature (55,73).
It is recognised, however, that cholecystectomy, 
especially with the addition of exploration of the 
common bile duct, and cardiac surgery using cardio­
pulmonary bypass both carry a significantly higher 
risk of post-operative acute pancreatitis than 
surgery at other sites distant from the pancreas 
(55,73). All studies in which the ACCR has been 
estimated after cholecystectomy have shown more 
striking changes in the ACCR in patients who have 
also undergone common bile duct exploration, a finding 
in keeping with clinical studies of acute pancreatitis 
following biliary surgery (55,57,58,59).
In this thesis an attempt was made to modify the 
ACCR response after biliary and cardiac surgery by 
using a drug and a technique respectively to protect 
the pancreas against the operative insults. In the 
case of biliary surgery Trasylol was used prophylactic- 
ally as a proteolytic enzyme inhibitor, while in 
cardiac surgery pulsatile cardiopulmonary bypass was 
used in order to improve the tissue blood flow through 
the pancreas and protect the gland against pancreatitis 
of ischaemic origin. In both instances these 
manouevres were successful in significantly reducing
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the ACCR response following biliary and cardiac surgery. 
These results provide strong indirect evidence that a 
significantly elevated ACCR in the absence of 
hyperamylasaemia or clinical signs of acute pancreatitis 
can indicate the presence of sub-clinical pancreatic 
inflammation. The evidence however is not indisputable 
and it remains possible, although very unlikely, that 
both Trasylol and pulsatile cardiopulmonary bypass act 
to reduce the ACCR following biliary and cardiac 
surgery by mechanisms not involving the pancreas.
The postulated ability of the ACCR to detect 
sub-clinical pancreatic inflammation was used to 
monitor the effects of Cimetidine therapy on the 
pancreas., A small but significant elevation in the 
ACCR was observed within 24 hours of starting 
intravenous Cimetidine therapy. The ACCR returned 
to normal within 72 hours and was not found to be
elevated during chronic administration of the drug.----
These findings support evidence in the literature 
that Cimetidine therapy may be associated with 
pancreatic inflammation (99,100) and demonstrate 
how the ACCR might be used to screen for sub-clinical 
pancreatic inflammation in situations where a small 
but significant incidence of acute pancreatitis has 
been observed.
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The presence of significant endotoxin in the 
blood of 40% of patients with acute pancreatitis and 
the increased activity of the complement system in 
all patients with acute pancreatitis were new and 
exciting observations which require to be followed 
up and hopefully put to clinical use. The finding 
of a highly significant correlation between the ACCR, 
estimated within 48 hours of admission to hospital 
with an attack of acute pancreatitis, and complement 
activation specifically via the classical pathway 
was both unexpected and stimulating. It seems clear 
that whatever activated the classical pathway also 
caused significant changes in the ACCR, In patients 
with established acute pancreatitis Trypsin seems by 
far the most likely candidate for this role, although 
other proteolytic enzymes released from the pancreas 
during an attack of acute pancreatitis cannot be 
excluded. This observation may be the best evidence 
to date that a substance released from the pancreas 
during an attack of acute pancreatitis is directly 
related to the changes in amylase clearance observed 
at that time. Further studies are required to confirm 
this finding and to relate the ACCR changes in acute 
pancreatitis to measured levels of Trypsin and its 
associated compounds. This finding is also entirely 
in keeping with the effect of Trasylol, an antitrypsin
agent, on the ACCR observed in Chapter 4 and supports 
the hypothesis put forward in that chapter.
4o CONCLUSIONS
In conclusion, therefore, the studies presented 
in this thesis have demonstrated that the ACCR is a 
simple test to perform and has a definite place in 
the diagnosis of acute pancreatitis. In these studies 
the ACCR achieved an overall 94% accuracy in the 
diagnosis of acute pancreatitis, including marked 
success in making the diagnosis in patients who for 
various reasons did not have significant hyperamylasaemia 
at the time of testing. The ACCR should be especially 
useful as a screening test for acute pancreatitis in 
patients admitted to hospital with abdominal pain of 
over 48 hours duration who have an amylase value above 
the normal range but below the level considered diagnostic 
for acute pancreatitis. There is good evidence that
the ACCR is a sensitive test for pancreatic inflammation 
and can detect sub-clinical states. There is serious 
doubt however regarding the specificity of a significantly 
elevated ACCR for pancreatic inflammation alone and this 
makes the interpretation of a significant ACCR elevation 
in the absence of hyperamylasaemia and clinical findings 
suggestive of acute pancreatitis extremely difficult.
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Despite this, the ACCR could be used to screen for 
pancreatic inflammation in situations where it might 
be expected to exist. The elevation of the ACCR in 
acute pancreatitis appears to be secondary to the 
release of Trypsin from the inflamed pancreas which 
results in reduced absorption of amylase from the 
renal tubules (38,39,40,41,42,135), Tliis, together 
with an Increase in amylase in the serum, leads to 
a rise in amylase clearance.
The ACCR is certainly not the ultimate diagnostic 
test for pancreatic inflammation and it is to be hoped 
that superior tests will be forthcoming in the near 
future. At the present time, however, the ACCR is 
as simple and at least as informative as any other 
diagnostic test in acute pancreatitis. The ACCR should 
be interpreted in conjunction with the serum amylase 
value by a clinician who understands the limitations 
of both tests. If these criteria are fulfilled then 
the ACCR is undoubtedly superior to any other single 
readily available diagnostic test for acute pancreatitis.
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A P P E N D I X
STATISTICAL ANALYSIS
The statistical analysis employed in the studies 
presented in this thesis was carried out using a 
programmable Hewlett Packard 9815A desk calculator. 
The following statistical tests were used where 
appropriate and reference was made to a text on 
medical statistics (136):
1. Student’s unpaired t test
2* Student’s paired t test
3, Fisher’s exact test
4. Linear regression analysis.
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